{ "version": "2.2", "instance": { "tivc20251231_10k.htm": { "nsprefix": "tivc", "nsuri": "http://www.tivichealth.com/20251231", "dts": { "schema": { "local": [ "tivc-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/exch/2025/exch-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "tivc-20251231_cal.xml" ] }, "definitionLink": { "local": [ "tivc-20251231_def.xml" ] }, "labelLink": { "local": [ "tivc-20251231_lab.xml" ] }, "presentationLink": { "local": [ "tivc-20251231_pre.xml" ] }, "inline": { "local": [ "tivc20251231_10k.htm" ] } }, "keyStandard": 411, "keyCustom": 134, "axisStandard": 38, "axisCustom": 0, "memberStandard": 40, "memberCustom": 105, "hidden": { "total": 102, "http://fasb.org/us-gaap/2025": 76, "http://www.tivichealth.com/20251231": 4, "http://xbrl.sec.gov/dei/2025": 6, "http://xbrl.sec.gov/ecd/2025": 6, "http://xbrl.sec.gov/cyd/2025": 10 }, "contextCount": 428, "entityCount": 1, "segmentCount": 155, "elementCount": 868, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2025": 1214, "http://xbrl.sec.gov/dei/2025": 38, "http://xbrl.sec.gov/cyd/2025": 16, "http://xbrl.sec.gov/ecd/2025": 7, "http://fasb.org/srt/2025": 1 }, "report": { "R1": { "role": "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:AssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R3": { "role": "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2025-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:PreferredStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "longName": "003 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R5": { "role": "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2023-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_StatementClassOfStockAxis-SeriesBPreferredStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "longName": "995443 - Disclosure - Award Timing Disclosure", "shortName": "Award Timing Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": null, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": null, "uniqueAnchor": null }, "R10": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.tivichealth.com/20251231/role/statement-note-1-formation-and-business-of-the-company", "longName": "995555 - Disclosure - Note 1 - Formation and Business of the Company", "shortName": "Note 1 - Formation and Business of the Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "995556 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "longName": "995557 - Disclosure - Note 3 - Discontinued Operations", "shortName": "Note 3 - Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination", "longName": "995558 - Disclosure - Note 4 - Business Combination", "shortName": "Note 4 - Business Combination", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-", "longName": "995559 - Disclosure - Note 5 - Financial Instruments and Fair Value Measurements", "shortName": "Note 5 - Financial Instruments and Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net", "longName": "995560 - Disclosure - Note 6 - Inventory, Net", "shortName": "Note 6 - Inventory, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "longName": "995561 - Disclosure - Note 7 - Property and Equipment, Net", "shortName": "Note 7 - Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "longName": "995562 - Disclosure - Note 8 - Statera License Agreement", "shortName": "Note 8 - Statera License Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:LicenseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:LicenseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies", "longName": "995563 - Disclosure - Note 9 - Commitments and Contingencies", "shortName": "Note 9 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses", "longName": "995564 - Disclosure - Note 10 - Other Accrued Expenses", "shortName": "Note 10 - Other Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "longName": "995565 - Disclosure - Note 11 - Convertible Note Payable", "shortName": "Note 11 - Convertible Note Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "longName": "995566 - Disclosure - Note 12 - Preferred Stock", "shortName": "Note 12 - Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "longName": "995567 - Disclosure - Note 13 - Common Stock", "shortName": "Note 13 - Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:CommonStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:CommonStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "longName": "995568 - Disclosure - Note 14 - Common Stock Warrants", "shortName": "Note 14 - Common Stock Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:WarrantsAndRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:WarrantsAndRightsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "longName": "995569 - Disclosure - Note 15 - Equity Incentive Plans", "shortName": "Note 15 - Equity Incentive Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "longName": "995570 - Disclosure - Note 16 - Income Taxes", "shortName": "Note 16 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share", "longName": "995571 - Disclosure - Note 17 - Net Loss per Share", "shortName": "Note 17 - Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements", "longName": "995572 - Disclosure - Note 18 - Revision of Previously Issued Financial Statements", "shortName": "Note 18 - Revision of Previously Issued Financial Statements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ErrorCorrectionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ErrorCorrectionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information", "longName": "995573 - Disclosure - Note 19 - Segment Information", "shortName": "Note 19 - Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "longName": "995574 - Disclosure - Note 20 - Subsequent Events", "shortName": "Note 20 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies", "longName": "995575 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-tables", "longName": "995576 - Disclosure - Note 3 - Discontinued Operations (Tables)", "shortName": "Note 3 - Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-tables", "longName": "995577 - Disclosure - Note 4 - Business Combination (Tables)", "shortName": "Note 4 - Business Combination (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-tables", "longName": "995578 - Disclosure - Note 5 - Financial Instruments and Fair Value Measurements (Tables)", "shortName": "Note 5 - Financial Instruments and Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-tables", "longName": "995579 - Disclosure - Note 6 - Inventory, Net (Tables)", "shortName": "Note 6 - Inventory, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-tables", "longName": "995580 - Disclosure - Note 7 - Property and Equipment, Net (Tables)", "shortName": "Note 7 - Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-tables", "longName": "995581 - Disclosure - Note 8 - Statera License Agreement (Tables)", "shortName": "Note 8 - Statera License Agreement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:ScheduleOfMilestonePaymentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "tivc:LicenseAgreementTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:ScheduleOfMilestonePaymentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "tivc:LicenseAgreementTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-tables", "longName": "995582 - Disclosure - Note 9 - Commitments and Contingencies (Tables)", "shortName": "Note 9 - Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-tables", "longName": "995583 - Disclosure - Note 10 - Other Accrued Expenses (Tables)", "shortName": "Note 10 - Other Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-tables", "longName": "995584 - Disclosure - Note 11 - Convertible Note Payable (Tables)", "shortName": "Note 11 - Convertible Note Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-tables", "longName": "995585 - Disclosure - Note 13 - Common Stock (Tables)", "shortName": "Note 13 - Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:SummaryOfReservedSharesOfStockTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "tivc:CommonStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:SummaryOfReservedSharesOfStockTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "tivc:CommonStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-tables", "longName": "995586 - Disclosure - Note 14 - Common Stock Warrants (Tables)", "shortName": "Note 14 - Common Stock Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "tivc:WarrantsAndRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "tivc:WarrantsAndRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-tables", "longName": "995587 - Disclosure - Note 15 - Equity Incentive Plans (Tables)", "shortName": "Note 15 - Equity Incentive Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-tables", "longName": "995588 - Disclosure - Note 16 - Income Taxes (Tables)", "shortName": "Note 16 - Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-tables", "longName": "995589 - Disclosure - Note 17 - Net Loss per Share (Tables)", "shortName": "Note 17 - Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-tables", "longName": "995590 - Disclosure - Note 18 - Revision of Previously Issued Financial Statements (Tables)", "shortName": "Note 18 - Revision of Previously Issued Financial Statements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ErrorCorrectionTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ErrorCorrectionTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-tables", "longName": "995591 - Disclosure - Note 19 - Segment Information (Tables)", "shortName": "Note 19 - Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995592 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:StockIssuedDuringPeriodSharesWholeSharesIssuedInsteadOfFractionalShares", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "tivc:ReverseStockSplitPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R49": { "role": "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "longName": "995593 - Disclosure - Note 3 - Discontinued Operations (Details Textual)", "shortName": "Note 3 - Discontinued Operations (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_DisposalGroupClassificationAxis-SegmentDiscontinuedOperationsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-ClearupMember", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_DisposalGroupClassificationAxis-SegmentDiscontinuedOperationsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-ClearupMember", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "longName": "995594 - Disclosure - Note 3 - Discontinued Operations - Significant Items from Discontinued Operations (Details)", "shortName": "Note 3 - Discontinued Operations - Significant Items from Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-details-textual", "longName": "995595 - Disclosure - Note 4 - Business Combination (Details Textual)", "shortName": "Note 4 - Business Combination (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "i_2025-12-09_BusinessAcquisitionAxis-ScorpiusHoldingsMember", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-09_BusinessAcquisitionAxis-ScorpiusHoldingsMember", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details", "longName": "995596 - Disclosure - Note 4 - Business Combination - Assets Acquired and Liabilities Assumed (Details)", "shortName": "Note 4 - Business Combination - Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_BusinessAcquisitionAxis-ScorpiusHoldingsMember", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R53": { "role": "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details", "longName": "995597 - Disclosure - Note 4 - Business Combination - Schedule of Pro Forma Information (Details)", "shortName": "Note 4 - Business Combination - Schedule of Pro Forma Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_BusinessAcquisitionAxis-ScorpiusHoldingsMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_BusinessAcquisitionAxis-ScorpiusHoldingsMember", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-details-textual", "longName": "995598 - Disclosure - Note 5 - Financial Instruments and Fair Value Measurements (Details Textual)", "shortName": "Note 5 - Financial Instruments and Fair Value Measurements (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R55": { "role": "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details", "longName": "995599 - Disclosure - Note 5 - Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents' Fair Value (Details)", "shortName": "Note 5 - Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents' Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "i_2025-12-31_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details", "longName": "995600 - Disclosure - Note 5 - Financial Instruments and Fair Value Measurements - Schedule of Recurring Fair Value Measurements (Details)", "shortName": "Note 5 - Financial Instruments and Fair Value Measurements - Schedule of Recurring Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "i_2024-12-31_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details", "longName": "995601 - Disclosure - Note 6 - Inventory, Net - Summary of Inventory (Details)", "shortName": "Note 6 - Inventory, Net - Summary of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual", "longName": "995602 - Disclosure - Note 7 - Property and Equipment, Net (Details Textual)", "shortName": "Note 7 - Property and Equipment, Net (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_DisposalGroupClassificationAxis-SegmentDiscontinuedOperationsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis-ClearupMember", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R59": { "role": "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details", "longName": "995603 - Disclosure - Note 7 - Property and Equipment, Net - Summary of Property and Equipment (Details)", "shortName": "Note 7 - Property and Equipment, Net - Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual", "longName": "995604 - Disclosure - Note 8 - Statera License Agreement (Details Textual)", "shortName": "Note 8 - Statera License Agreement (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2025-06-18_TypeOfArrangementAxis-AmendedAndRestatedExclusiveLicenseAgreementMember", "name": "tivc:LicenseAgreementMaximumLienPayoffAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "tivc:LicenseAgreementTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-06-18_TypeOfArrangementAxis-AmendedAndRestatedExclusiveLicenseAgreementMember", "name": "tivc:LicenseAgreementMaximumLienPayoffAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "tivc:LicenseAgreementTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details", "longName": "995605 - Disclosure - Note 8 - Statera License Agreement - Schedule of Milestone Payments (Details)", "shortName": "Note 8 - Statera License Agreement - Schedule of Milestone Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "d_2025-02-11_2025-02-11_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ValidationOfCurrentInventoryOfMaterialsForDistributionAndSalesMember_TypeOfArrangementAxis-StateraLicenseAgreementMember", "name": "tivc:LicenseAgreementMilestonePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "tivc:ScheduleOfMilestonePaymentsTableTextBlock", "tivc:LicenseAgreementTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-02-11_2025-02-11_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-ValidationOfCurrentInventoryOfMaterialsForDistributionAndSalesMember_TypeOfArrangementAxis-StateraLicenseAgreementMember", "name": "tivc:LicenseAgreementMilestonePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "tivc:ScheduleOfMilestonePaymentsTableTextBlock", "tivc:LicenseAgreementTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual", "longName": "995606 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)", "shortName": "Note 9 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details", "longName": "995607 - Disclosure - Note 9 - Commitments and Contingencies - Lease Costs (Details)", "shortName": "Note 9 - Commitments and Contingencies - Lease Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details", "longName": "995608 - Disclosure - Note 10 - Other Accrued Expenses - Summary of Other Accrued Expenses (Details)", "shortName": "Note 10 - Other Accrued Expenses - Summary of Other Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "longName": "995609 - Disclosure - Note 11 - Convertible Note Payable (Details Textual)", "shortName": "Note 11 - Convertible Note Payable (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2025-12-09", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-09", "name": "tivc:ConvertibleNoteAndWarrantsPurchasePrice", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R66": { "role": "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details", "longName": "995610 - Disclosure - Note 11 - Convertible Note Payable - Schedule of Note Payable (Details)", "shortName": "Note 11 - Convertible Note Payable - Schedule of Note Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:ConvertibleDebtNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_DebtInstrumentAxis-ConvertibleNoteMember", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R67": { "role": "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details", "longName": "995611 - Disclosure - Note 11 - Convertible Note Payable - Future Payments of the Note Payable (Details)", "shortName": "Note 11 - Convertible Note Payable - Future Payments of the Note Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "i_2025-12-31_DebtInstrumentAxis-ConvertibleNoteMember", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_DebtInstrumentAxis-ConvertibleNoteMember", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "longName": "995612 - Disclosure - Note 12 - Preferred Stock (Details Textual)", "shortName": "Note 12 - Preferred Stock (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "d_2024-05-01_2024-05-31", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "tivc:WarrantsAndRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-09_DebtInstrumentAxis-ConvertibleNoteMember", "name": "tivc:DebtInstrumentConvertibleMaximumSharesIssuablePercentOfOutstanding", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:PreferredStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R69": { "role": "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "longName": "995613 - Disclosure - Note 13 - Common Stock (Details Textual)", "shortName": "Note 13 - Common Stock (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "i_2025-03-07", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "tivc:CommonStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DividendsCommonStock", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "tivc:CommonStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R70": { "role": "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details", "longName": "995614 - Disclosure - Note 13 - Common Stock - Summary of Reserved Shares of Common Stock (Details)", "shortName": "Note 13 - Common Stock - Summary of Reserved Shares of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "tivc:SummaryOfReservedSharesOfStockTableTextBlock", "tivc:CommonStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "tivc:SummaryOfReservedSharesOfStockTableTextBlock", "tivc:CommonStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "longName": "995615 - Disclosure - Note 14 - Common Stock Warrants (Details Textual)", "shortName": "Note 14 - Common Stock Warrants (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "d_2024-05-01_2024-05-31", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "tivc:WarrantsAndRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-05-01_2024-05-31", "name": "tivc:ClassOfWarrantOrRightIssuedFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "p", "tivc:WarrantsAndRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R72": { "role": "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details", "longName": "995616 - Disclosure - Note 14 - Common Stock Warrants - Fair Value Measurements of Warrants (Details)", "shortName": "Note 14 - Common Stock Warrants - Fair Value Measurements of Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "i_2025-12-31_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "tivc:WarrantsAndRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "tivc:WarrantsAndRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details", "longName": "995617 - Disclosure - Note 14 - Common Stock Warrants - Summary of Outstanding Warrants (Details)", "shortName": "Note 14 - Common Stock Warrants - Summary of Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "tivc:WarrantsAndRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "tivc:WarrantsAndRightsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "longName": "995618 - Disclosure - Note 15 - Equity Incentive Plans (Details Textual)", "shortName": "Note 15 - Equity Incentive Plans (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R75": { "role": "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details", "longName": "995619 - Disclosure - Note 15 - Equity Incentive Plans - Options Activity (Details)", "shortName": "Note 15 - Equity Incentive Plans - Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "tivc:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R76": { "role": "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "longName": "995620 - Disclosure - Note 15 - Equity Incentive Plans - Fair Value of Shared-based Payment Awards (Details)", "shortName": "Note 15 - Equity Incentive Plans - Fair Value of Shared-based Payment Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31_PlanNameAxis-Ar2021PlanAmendedMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_PlanNameAxis-Ar2021PlanAmendedMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details", "longName": "995621 - Disclosure - Note 15 - Equity Incentive Plans - Summary of Restricted Stock Awards (Details)", "shortName": "Note 15 - Equity Incentive Plans - Summary of Restricted Stock Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "i_2024-12-31_AwardTypeAxis-RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_AwardTypeAxis-RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R78": { "role": "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details", "longName": "995622 - Disclosure - Note 15 - Equity Incentive Plans - Summary of Stock-based Compensation (Details)", "shortName": "Note 15 - Equity Incentive Plans - Summary of Stock-based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R79": { "role": "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual", "longName": "995623 - Disclosure - Note 16 - Income Taxes (Details Textual)", "shortName": "Note 16 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "longName": "995624 - Disclosure - Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "shortName": "Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R81": { "role": "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "longName": "995625 - Disclosure - Note 16 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "shortName": "Note 16 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-unrecognized-tax-benefits-details", "longName": "995626 - Disclosure - Note 16 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)", "shortName": "Note 16 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": null }, "R83": { "role": "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "longName": "995627 - Disclosure - Note 17 - Net Loss per Share - Calculation of Earnings per Share (Details)", "shortName": "Note 17 - Net Loss per Share - Calculation of Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "tivc:DeemedDividendsOnPurchaseWarrantsForCommonShares", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R84": { "role": "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details", "longName": "995628 - Disclosure - Note 17 - Net Loss per Share - Summary of Antidilutive Securities (Details)", "shortName": "Note 17 - Net Loss per Share - Summary of Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details", "longName": "995629 - Disclosure - Note 18 - Revision of Previously Issued Financial Statements - Schedule of Revised Financial Statements (Details)", "shortName": "Note 18 - Revision of Previously Issued Financial Statements - Schedule of Revised Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:AdditionalPaidInCapital", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-09-30", "name": "us-gaap:AdditionalPaidInCapital", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "us-gaap:ErrorCorrectionTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R86": { "role": "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-details-textual", "longName": "995630 - Disclosure - Note 19 - Segment Information (Details Textual)", "shortName": "Note 19 - Segment Information (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": null, "uniqueAnchor": null }, "R87": { "role": "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details", "longName": "995631 - Disclosure - Note 19 - Segment Information - Schedule of Segment Information (Details)", "shortName": "Note 19 - Segment Information - Schedule of Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_StatementBusinessSegmentsAxis-BiopharmaMember", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } }, "R88": { "role": "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "longName": "995632 - Disclosure - Note 20 - Subsequent Events (Details Textual)", "shortName": "Note 20 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "i_2025-12-09", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2026-03-13_LeaseContractualTermAxis-MicrobialBuildingLeaseMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:AreaOfRealEstateProperty", "unitRef": "SquareFoot", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "tivc20251231_10k.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r79", "r81", "r86", "r1255" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r79", "r1076" ] }, "tivc_AccruedConsultingFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "AccruedConsultingFeesCurrent", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "tivc_AccruedConsultingFeesCurrent", "terseLabel": "Consulting fees", "documentation": "Accrued consulting fees." } } }, "auth_ref": [] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedEmployeeBenefitsCurrent", "terseLabel": "Payroll liabilities", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r81" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedProfessionalFeesCurrent", "terseLabel": "Legal and professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r81" ] }, "tivc_AccruedResearchStudyCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "AccruedResearchStudyCostsCurrent", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "tivc_AccruedResearchStudyCostsCurrent", "terseLabel": "Research study costs", "documentation": "Accrued research study costs." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r44", "r196", "r834" ] }, "tivc_AcuteRadiationSyndromeDevelopmentMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "AcuteRadiationSyndromeDevelopmentMilestonesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Acute Radiation Syndrome Development Milestones [Member]", "documentation": "Acute Radiation Syndrome Development Milestones." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r94", "r1076", "r1347" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r883", "r1178", "r1179", "r1180", "r1183", "r1281", "r1351" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Amortization of debt discount and debt issuance costs", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r9" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "terseLabel": "Dividends declared on preferred stock", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance." } } }, "auth_ref": [ "r15", "r125" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r513" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r15", "r46", "r125" ] }, "tivc_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForServices", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants to placement agents as non-cash offering fees", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r545", "r554", "r564" ] }, "tivc_AmendedAndRestatedExclusiveLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "AmendedAndRestatedExclusiveLicenseAgreementMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Amended and Restated Exclusive License Agreement [Member]", "documentation": "The A&R License Agreement." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r314" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r314" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r314" ] }, "tivc_Ar2021PlanAmendedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "Ar2021PlanAmendedMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "A&R 2021 Plan, Amended [Member]", "documentation": "The second amendment to the 2021 A&R Plan." } } }, "auth_ref": [] }, "tivc_Ar2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "Ar2021PlanMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "A&R 2021 Plan [Member]", "documentation": "The Amended and Restated 2021 Plan." } } }, "auth_ref": [] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AreaOfRealEstateProperty", "terseLabel": "Area of Real Estate Property (Square Foot)", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r697" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r393", "r395", "r396", "r397", "r398", "r399", "r871", "r1270" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetAcquisitionConsiderationTransferred", "terseLabel": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r1053", "r1271", "r1272", "r1273" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "terseLabel": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable", "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r1271", "r1272", "r1273" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost", "terseLabel": "Asset Acquisition, Consideration Transferred, Transaction Cost", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r1053", "r1271", "r1272", "r1273" ] }, "tivc_AssetAcquisitionContingentConsiderationTrancheOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "AssetAcquisitionContingentConsiderationTrancheOne", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_AssetAcquisitionContingentConsiderationTrancheOne", "terseLabel": "Asset Acquisition, Contingent Consideration, Tranche One", "documentation": "Asset Acquisition, Contingent Consideration, Tranche One" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r393", "r395", "r396", "r397", "r398", "r399", "r871", "r1270" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Total consolidated assets of continuing operations", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r135", "r145", "r199", "r271", "r274", "r275", "r319", "r331", "r356", "r360", "r371", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r698", "r700", "r767", "r819", "r820", "r826", "r925", "r1011", "r1012", "r1024", "r1076", "r1079", "r1080", "r1091", "r1214", "r1215", "r1303" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r191", "r205", "r271", "r274", "r275", "r371", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r698", "r700", "r767", "r1076", "r1214", "r1215", "r1303" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsFairValueDisclosure", "terseLabel": "Total assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r734", "r735", "r1057" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Current assets of discontinued operations", "totalLabel": "Total current assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r58", "r74", "r113", "r116", "r189", "r190" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1095", "r1096", "r1109" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r1095", "r1096", "r1109" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r1095", "r1096", "r1109" ] }, "tivc_AvenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "AvenueMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Avenue [Member]", "documentation": "Avenue." } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r1112" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "ecd_AwardTmgMnpiCnsdrdFlag", "terseLabel": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1112" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1112" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r540", "r541", "r542", "r543", "r544" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r1169" ] }, "tivc_BiopharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "BiopharmaMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Biopharma [Member]", "documentation": "Relating to Biopharma." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details" ], "lang": { "en-us": { "role": { "label": "Business Combination [Domain]", "documentation": "Business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r393", "r395", "r396", "r397", "r398", "r399", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r663", "r664", "r665", "r666", "r667", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r688", "r689", "r690", "r871", "r1031", "r1032", "r1263", "r1265", "r1267" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details" ], "lang": { "en-us": { "role": { "label": "Business Combination [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r393", "r395", "r396", "r397", "r398", "r399", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r663", "r664", "r665", "r666", "r667", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r688", "r689", "r690", "r871", "r1031", "r1032", "r1263", "r1265", "r1267" ] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details" ], "lang": { "en-us": { "role": { "label": "Pro forma earnings per share (in dollars per share)", "documentation": "Per basic share amount, after tax, of pro forma income (loss) of combined entity as if acquisition date of business combination occurred as of beginning of period." } } }, "auth_ref": [ "r1134", "r1135", "r1264" ] }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details" ], "lang": { "en-us": { "role": { "label": "Business Combination, Pro Forma Information [Table]", "documentation": "Disclosure of information about pro forma revenue and earnings for business combination or aggregate of series of individually immaterial business combinations." } } }, "auth_ref": [ "r640", "r641", "r642", "r643", "r644", "r645", "r1038", "r1050" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-tables" ], "lang": { "en-us": { "role": { "label": "Business Combination, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma revenue and earnings for business combination or aggregate of series of individually immaterial business combinations." } } }, "auth_ref": [ "r1038", "r1049", "r1134", "r1135", "r1264" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details" ], "lang": { "en-us": { "role": { "label": "Pro forma net income (loss)", "documentation": "Amount, after tax, of pro forma income (loss) of combined entity as if acquisition date of business combination occurred as of beginning of period." } } }, "auth_ref": [ "r642", "r643", "r645", "r1038", "r1049", "r1050" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details" ], "lang": { "en-us": { "role": { "label": "Pro forma revenue", "documentation": "Amount of pro forma revenue of combined entity as if acquisition date of business combination occurred as of beginning of period." } } }, "auth_ref": [ "r642", "r643", "r645", "r1038", "r1049" ] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "terseLabel": "Business Combination, Consideration Transferred, Liabilities Incurred", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [ "r677", "r1038", "r1043", "r1052" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination" ], "lang": { "en-us": { "role": { "label": "Business Combination [Text Block]", "documentation": "The entire disclosure for business combination." } } }, "auth_ref": [ "r624", "r627", "r631", "r640", "r644", "r645", "r646", "r647", "r648", "r649", "r651", "r652", "r658", "r661", "r662", "r668", "r672", "r673", "r681", "r685", "r686", "r687", "r689", "r691", "r1038", "r1039", "r1040", "r1041", "r1045", "r1046", "r1047" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "totalLabel": "Total current assets", "documentation": "Amount of asset acquired in business combination and recognized at acquisition date, classified as current." } } }, "auth_ref": [ "r1266", "r1268" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other current assets", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "documentation": "Amount of prepaid expense and asset classified as other, acquired in business combination and recognized at acquisition date, classified as current." } } }, "auth_ref": [ "r1266", "r1268" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "terseLabel": "Business Combination, Recognized Liability Assumed, Liability", "documentation": "Amount of liability assumed in business combination and recognized at acquisition date." } } }, "auth_ref": [ "r656", "r661" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, net", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "documentation": "Amount of property, plant, and equipment acquired in business combination and recognized at acquisition date." } } }, "auth_ref": [ "r1038", "r1043", "r1266", "r1268" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "totalLabel": "Total assets", "documentation": "Amount of asset acquired in excess of (less than) liability assumed plus goodwill in business combination and recognized at acquisition date." } } }, "auth_ref": [ "r1266", "r1268" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Business Combination [Policy Text Block]", "documentation": "Disclosure of accounting policy for business combination." } } }, "auth_ref": [ "r625", "r626", "r632", "r634", "r645", "r657", "r661", "r1038", "r1044", "r1051", "r1052" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r761", "r762", "r766", "r985", "r1292" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalent", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r27", "r194", "r986" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r194" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Money market funds", "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r759", "r761", "r762", "r1283", "r1284" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r28" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents included in continuing operations", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r27", "r106", "r268" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Less: cash and cash equivalents included in discontinued operations", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r27", "r106", "r268" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Beginning of period", "periodEndLabel": "End of period", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r27", "r106", "r268" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r1", "r106" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashEquivalentsAtCarryingValue", "terseLabel": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r1144", "r1314" ] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Net cash used in operating activities - discontinued operations", "label": "Net cash used in operating activities - discontinued operations", "documentation": "Amount of cash inflow (outflow) from operating activity attributable to discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r73", "r106" ] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashUninsuredAmount", "terseLabel": "Cash, Uninsured Amount", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "tivc_CdmoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CdmoMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "CDMO [Member]", "documentation": "Relating to CDMO." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r157", "r200", "r201", "r202", "r271", "r275", "r306", "r307", "r310", "r313", "r321", "r322", "r371", "r426", "r428", "r429", "r430", "r433", "r434", "r468", "r469", "r471", "r472", "r474", "r478", "r480", "r481", "r484", "r485", "r487", "r767", "r877", "r878", "r879", "r880", "r883", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r913", "r933", "r951", "r970", "r971", "r972", "r973", "r974", "r1131", "r1172", "r1174", "r1184" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r1224" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "tivc_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ClassOfWarrantOrRightExercisable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ClassOfWarrantOrRightExercisable", "terseLabel": "Class of Warrant or Right, Exercisable (in shares)", "documentation": "Class of Warrant or Right, Exercisable" } } }, "auth_ref": [] }, "tivc_ClassOfWarrantOrRightExercisableExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ClassOfWarrantOrRightExercisableExercisePrice", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ClassOfWarrantOrRightExercisableExercisePrice", "terseLabel": "Class of Warrant or Right, Exercisable, Exercise Price (in dollars per share)", "documentation": "Class of Warrant or Right, Exercisable, Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Exercise price of warrants (in dollars per share)", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r271", "r278", "r488" ] }, "tivc_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentOfClosingPricePerShare": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentOfClosingPricePerShare", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentOfClosingPricePerShare", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Closing Price per Share", "documentation": "The exercise price of the warrant or rights, equal to the given percent of the closing price per share." } } }, "auth_ref": [] }, "tivc_ClassOfWarrantOrRightExercisesDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ClassOfWarrantOrRightExercisesDuringPeriod", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ClassOfWarrantOrRightExercisesDuringPeriod", "terseLabel": "Class of Warrant or Right, Exercises During Period (in shares)", "documentation": "The number of warrants or rights exercised during the period" } } }, "auth_ref": [] }, "tivc_ClassOfWarrantOrRightExpiredDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ClassOfWarrantOrRightExpiredDuringPeriod", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ClassOfWarrantOrRightExpiredDuringPeriod", "terseLabel": "Class of Warrant or Right, Expired During Period (in shares)", "documentation": "The number of warrants or rights expired during the period." } } }, "auth_ref": [] }, "tivc_ClassOfWarrantOrRightIssuedFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ClassOfWarrantOrRightIssuedFairValue", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ClassOfWarrantOrRightIssuedFairValue", "terseLabel": "Class of Warrant or Right, Issued, Fair Value", "documentation": "Class of Warrant or Right, Issued, Fair Value" } } }, "auth_ref": [] }, "tivc_ClassOfWarrantOrRightIssuedWithCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ClassOfWarrantOrRightIssuedWithCommonStock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ClassOfWarrantOrRightIssuedWithCommonStock", "terseLabel": "Class of Warrant or Right, Issued with Common Stock (in shares)", "documentation": "The warrants issued with each share of common stock." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r488" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Number of warrant shares (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-tables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r1224" ] }, "tivc_ClearupMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ClearupMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual" ], "lang": { "en-us": { "role": { "label": "ClearUP [Member]", "documentation": "ClearUP" } } }, "auth_ref": [] }, "tivc_CommissionFee": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommissionFee", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_CommissionFee", "terseLabel": "Commission Fee", "documentation": "The commission fee percent." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES (Note 9)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r87", "r139", "r827", "r912" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r119", "r417", "r418", "r979", "r1207", "r1212" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r45", "r980" ] }, "tivc_CommonStockAggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommonStockAggregateOfferingPrice", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_CommonStockAggregateOfferingPrice", "terseLabel": "Common Stock, Aggregate Offering Price", "documentation": "The aggregate offering price of all common stock." } } }, "auth_ref": [] }, "tivc_CommonStockAvailableForConversionOfSeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommonStockAvailableForConversionOfSeriesAPreferredStockMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock Available for Conversion of Series A Preferred Stock [Member]", "documentation": "Common Stock Available for Conversion of Series A Preferred Stock" } } }, "auth_ref": [] }, "tivc_CommonStockAvailableForConversionOfSeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommonStockAvailableForConversionOfSeriesBPreferredStockMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock Available for Conversion of Series B Preferred Stock [Member]", "documentation": "Common Stock Available for Conversion of Series B Preferred Stock" } } }, "auth_ref": [] }, "tivc_CommonStockAvailableForConversionOfSeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommonStockAvailableForConversionOfSeriesCPreferredStockMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock Available for Conversion of Series C Preferred Stock [Member]", "documentation": "Common Stock Available for Conversion of Series C Preferred Stock" } } }, "auth_ref": [] }, "tivc_CommonStockAvailableForFutureIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommonStockAvailableForFutureIncentivePlanMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock Available for Future Incentive Plan [Member]", "documentation": "Common Stock Available for Future Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r93" ] }, "tivc_CommonStockFromOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommonStockFromOptionsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock from Options [Member]", "documentation": "Common Stock from Options" } } }, "auth_ref": [] }, "tivc_CommonStockFromRsusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommonStockFromRsusMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock from RSUs [Member]", "documentation": "Common Stock from RSUs" } } }, "auth_ref": [] }, "tivc_CommonStockFromWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommonStockFromWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock from Warrants [Member]", "documentation": "Common Stock from Warrants" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1081", "r1082", "r1083", "r1085", "r1086", "r1087", "r1088", "r1178", "r1179", "r1183", "r1281", "r1345", "r1351" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r93" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r93", "r913" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, issued (in shares)", "terseLabel": "Common Stock, Shares, Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r93" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, outstanding (in shares)", "terseLabel": "Common Stock, Shares, Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r93", "r913", "r931", "r1351", "r1352" ] }, "tivc_CommonStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommonStockTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock" ], "lang": { "en-us": { "role": { "label": "Common Stock [Text Block]", "documentation": "Disclosure of common stock." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.0001 par value, 200,000,000 shares authorized; 2,525,778 and 556,902 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r93", "r469", "r477", "r829", "r1076" ] }, "tivc_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "CommonStockWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]", "documentation": "Common stock warrants." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument." } } }, "auth_ref": [ "r764", "r765" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r55", "r1000" ] }, "tivc_ConsultingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConsultingAgreementMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Consulting Agreement [Member]", "documentation": "The consulting agreement." } } }, "auth_ref": [] }, "tivc_ConsultingFeeMonthly": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConsultingFeeMonthly", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ConsultingFeeMonthly", "terseLabel": "Consulting Fee, Monthly", "documentation": "The monthly fee payable on the consulting agreement." } } }, "auth_ref": [] }, "tivc_ConsultingFeeTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConsultingFeeTerm", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ConsultingFeeTerm", "terseLabel": "Consulting Fee, Term (Year)", "documentation": "The length of time that the consulting fees will be payable every month." } } }, "auth_ref": [] }, "tivc_ContinuingAndDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ContinuingAndDiscontinuedOperationsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "Continuing and Discontinued Operations [Member]", "documentation": "Relating to continuing and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerRefundLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ContractWithCustomerRefundLiability", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerRefundLiability", "terseLabel": "Contract with Customer, Refund Liability", "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer." } } }, "auth_ref": [ "r1225" ] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-tables" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r1143", "r1171", "r1177", "r1312" ] }, "tivc_ConversionOfSeriesAPreferredStockIntoCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConversionOfSeriesAPreferredStockIntoCommonMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Series A Preferred Stock into Common [Member]", "documentation": "The conversion of Series A preferred stock into common." } } }, "auth_ref": [] }, "tivc_ConversionOfSeriesBPreferredStockIntoCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConversionOfSeriesBPreferredStockIntoCommonMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Series B Preferred Stock into Common [Member]", "documentation": "The conversion of Series B preferred stock into common." } } }, "auth_ref": [] }, "tivc_ConversionOfSeriesCPreferredStockIntoCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConversionOfSeriesCPreferredStockIntoCommonStockMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Series C Preferred Stock into Common Stock [Member]", "documentation": "Conversion of Series C Preferred Stock into Common Stock" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "tivc_ConversionOfStockInitialOwnershipLimit": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConversionOfStockInitialOwnershipLimit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ConversionOfStockInitialOwnershipLimit", "terseLabel": "Conversion of Stock, Initial Ownership Limit", "documentation": "The initial maximum percent amount of common stock that may be owned after conversion." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockNameDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "tivc_ConversionOfStockOwnershipPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConversionOfStockOwnershipPercent", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ConversionOfStockOwnershipPercent", "terseLabel": "Conversion of Stock, Ownership Percent", "documentation": "The percent ownership of common stock after the conversion of stock." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConversionOfStockSharesConverted1", "terseLabel": "Conversion of Stock, Shares Converted (in shares)", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConversionOfStockSharesIssued1", "terseLabel": "Conversion of Stock, Shares Issued (in shares)", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "tivc_ConversionOfWarrantOwnershipPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConversionOfWarrantOwnershipPercent", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ConversionOfWarrantOwnershipPercent", "terseLabel": "Conversion of Warrant, Ownership Percent", "documentation": "The percent of stock ownable after the conversion of warrants." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 }, "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details" ], "lang": { "en-us": { "role": { "label": "Convertible note payable, net", "totalLabel": "Convertible note payable, net", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r20" ] }, "tivc_ConvertibleNoteAndWarrantsPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConvertibleNoteAndWarrantsPurchasePrice", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ConvertibleNoteAndWarrantsPurchasePrice", "terseLabel": "Convertible Note and Warrants, Purchase Price", "documentation": "Convertible Note and Warrants, Purchase Price" } } }, "auth_ref": [] }, "tivc_ConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ConvertibleNoteMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Convertible Note [Member]", "documentation": "Convertible Note" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r166", "r167", "r271", "r280", "r281", "r439", "r483", "r803", "r812", "r825", "r989", "r991", "r992", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1276", "r1277", "r1278", "r1279" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1104", "r1123" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1104", "r1123" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r1106", "r1125" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1106", "r1125" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r1108", "r1127" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1106", "r1125" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1099", "r1118" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1100", "r1119" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1100", "r1119" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1098", "r1117" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r1098", "r1117" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r1098", "r1117" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1101", "r1120" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1103", "r1122" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1103", "r1122" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1104", "r1123" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1107", "r1126" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1105", "r1124" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1102", "r1121" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r120", "r271", "r273", "r407", "r408", "r409", "r410", "r411", "r424", "r425", "r435", "r441", "r442", "r443", "r444", "r445", "r446", "r451", "r458", "r459", "r461", "r707", "r778" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r80", "r81", "r136", "r138", "r436", "r437", "r438", "r439", "r440", "r442", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r1019", "r1020", "r1021", "r1022", "r1023", "r1066", "r1170", "r1171", "r1173", "r1177", "r1208", "r1209", "r1210", "r1295", "r1296", "r1312" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details": { "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details" ], "lang": { "en-us": { "role": { "label": "Issuance of convertible note payable", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r20", "r138", "r462" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1", "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r121", "r438" ] }, "tivc_DebtInstrumentConvertibleMaximumConvertibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DebtInstrumentConvertibleMaximumConvertibleAmount", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_DebtInstrumentConvertibleMaximumConvertibleAmount", "terseLabel": "Debt Instrument, Convertible, Maximum Convertible Amount", "documentation": "The maximum value the debt instrument may be converted to." } } }, "auth_ref": [] }, "tivc_DebtInstrumentConvertibleMaximumRedeemableAmountPercentOfNetProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DebtInstrumentConvertibleMaximumRedeemableAmountPercentOfNetProceeds", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_DebtInstrumentConvertibleMaximumRedeemableAmountPercentOfNetProceeds", "terseLabel": "Debt Instrument, Convertible, Maximum Redeemable Amount, Percent of Net Proceeds", "documentation": "The maximum redeemable amount of the convertible debt instrument, as a percent of the net proceeds of the conversion." } } }, "auth_ref": [] }, "tivc_DebtInstrumentConvertibleMaximumSharesIssuablePercentOfOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DebtInstrumentConvertibleMaximumSharesIssuablePercentOfOutstanding", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_DebtInstrumentConvertibleMaximumSharesIssuablePercentOfOutstanding", "terseLabel": "Debt Instrument, Convertible, Maximum Shares Issuable, Percent of Outstanding", "documentation": "The maximum percent of shares issuable on the convertible debt instrument, as a percent of the total number of outstanding shares." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentConvertibleStockPriceTrigger", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleStockPriceTrigger", "terseLabel": "Debt Instrument, Convertible, Stock Price Trigger (in dollars per share)", "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "terseLabel": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "tivc_DebtInstrumentConvertibleredemptionPricePercentOfInstallmentAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DebtInstrumentConvertibleredemptionPricePercentOfInstallmentAmount", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_DebtInstrumentConvertibleredemptionPricePercentOfInstallmentAmount", "terseLabel": "Debt Instrument, Convertible,Redemption Price, Percent of Installment Amount", "documentation": "The redemption price of the convertible debt instrument, as a percent of the installment amount to be redeemed." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r436", "r778", "r779", "r1020", "r1021", "r1066" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFeeAmount", "terseLabel": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r84" ] }, "tivc_DebtInstrumentInterestRateDefault": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DebtInstrumentInterestRateDefault", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_DebtInstrumentInterestRateDefault", "terseLabel": "Debt Instrument, Interest Rate, Default", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement, in the event of default." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r83", "r437" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r20", "r436", "r437", "r438", "r439", "r440", "r442", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r1019", "r1020", "r1021", "r1022", "r1023", "r1066", "r1170", "r1171", "r1173", "r1177", "r1208", "r1209", "r1210", "r1295", "r1296", "r1312" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r20", "r49", "r52", "r56", "r123", "r124", "r436", "r437", "r438", "r439", "r440", "r442", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r460", "r707", "r822", "r1019", "r1020", "r1021", "r1022", "r1023", "r1066", "r1170", "r1171", "r1173", "r1177", "r1295", "r1296" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details": { "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscount", "terseLabel": "Debt Instrument, Unamortized Discount", "negatedLabel": "Debt discount, net", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r1217", "r1294", "r1295", "r1296" ] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": [ "r13" ] }, "tivc_DeemedDividendsOnPurchaseWarrantsForCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DeemedDividendsOnPurchaseWarrantsForCommonShares", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details": { "parentTag": "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "tivc_DeemedDividendsOnPurchaseWarrantsForCommonShares", "negatedTerseLabel": "Deemed dividends on warrants", "documentation": "Represents the amount of deemed dividends related to purchase warrants for common shares during the period." } } }, "auth_ref": [] }, "tivc_DeemedDividendsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DeemedDividendsPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Deemed Dividends [Policy Text Block]", "documentation": "Represents the disclosure of the policy for deemed dividends reported by the entity." } } }, "auth_ref": [] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Deferred Charges, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r198" ] }, "us-gaap_DeferredCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredCosts", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Deferred offering costs", "terseLabel": "Deferred Costs, Noncurrent", "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent." } } }, "auth_ref": [ "r134", "r1145" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details": { "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsNet", "negatedLabel": "Debt issuance costs, net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1217", "r1294", "r1295", "r1296" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Total Deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r88", "r89", "r137", "r594" ] }, "tivc_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development costs", "label": "tivc_DeferredTaxAssetsCapitalizedResearchAndDevelopment", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as Research and Development Costs." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsGross", "negatedTotalLabel": "Total Deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r595" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net Deferred tax assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1259" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Deferred tax assets recognized", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1259" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1261" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other temporary differences", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1261" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development credits", "label": "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r1261" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Less: Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r596" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill", "negatedTerseLabel": "Goodwill", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill." } } }, "auth_ref": [ "r1261" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation", "label": "us-gaap_Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r43", "r259", "r993", "r994", "r996", "r998" ] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments, Liabilities [Member]", "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect." } } }, "auth_ref": [ "r750" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative liability", "label": "us-gaap_DerivativeLiabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r206", "r207", "r706", "r734", "r735", "r749", "r759", "r761", "r762", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r926", "r928", "r929", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r988", "r990", "r991", "r992", "r1285", "r1286", "r1287", "r1346" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Derivative liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r207" ] }, "us-gaap_DisaggregationOfIncomeStatementExpenseCaptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfIncomeStatementExpenseCaptionTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-tables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Income Statement Expense, Caption [Table]", "documentation": "Disclosure of information about disaggregation of statement of income expense caption." } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r993", "r994", "r996", "r998" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r511", "r515", "r546", "r547", "r549", "r1034" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-1-formation-and-business-of-the-company", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r189" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "terseLabel": "Accounts receivable", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r58", "r74", "r116" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "terseLabel": "Other accrued expenses", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r58", "r74", "r113", "r116" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Non-current assets of discontinued operations", "totalLabel": "Total non-current assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r3", "r58", "r74", "r116", "r189", "r190" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "terseLabel": "Cost of Sales", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r72", "r190" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "totalLabel": "Gross Profit", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r72", "r190" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1", "terseLabel": "Disposal Group, Including Discontinued Operation, Inventory", "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r58", "r74", "r116" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "terseLabel": "Inventory, net", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r58", "r74", "r113", "r116" ] }, "tivc_DisposalGroupIncludingDiscontinuedOperationLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DisposalGroupIncludingDiscontinuedOperationLossOnDispositionOfAssets", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "tivc_DisposalGroupIncludingDiscontinuedOperationLossOnDispositionOfAssets", "negatedTerseLabel": "Loss on disposal of assets", "documentation": "Amount of loss on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "totalLabel": "Total operating expenses", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r72" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "totalLabel": "Loss from discontinued operations", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r72" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r58", "r74", "r113", "r116" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "terseLabel": "Property and equipment, net", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r3", "r58", "r74", "r116" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue", "terseLabel": "Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r72", "r190" ] }, "tivc_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "tivc_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "terseLabel": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r9", "r10", "r115", "r219" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r57", "r111" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r405", "r406", "r1031", "r1032" ] }, "tivc_DistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DistributionAgreementMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Distribution Agreement [Member]", "documentation": "The Distribution Agreement." } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DividendsCommonStock", "terseLabel": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r6", "r125" ] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_DividendsPreferredStock", "negatedLabel": "Dividends declared on preferred stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r6", "r125" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1095", "r1096", "r1109" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1095", "r1096", "r1109", "r1111" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1110" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DomesticCountryMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r576" ] }, "tivc_DrugSubstanceCareStorageAndHandlingLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DrugSubstanceCareStorageAndHandlingLeaseMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Drug Substance Care, Storage, and Handling Lease [Member]", "documentation": "The lease for the care, storage, and handling of drug substances." } } }, "auth_ref": [] }, "tivc_DrugSubstancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "DrugSubstancesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Drug Substances [Member]", "documentation": "Drug substances." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Net loss per share attributed to common stockholders - basic and diluted (in dollars per share)", "terseLabel": "Net loss per share - basic and diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r181", "r214", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r299", "r305", "r306", "r310", "r312", "r313", "r318", "r467", "r552", "r622", "r696", "r731", "r732", "r818", "r840", "r1002" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r36", "r37", "r315" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r304", "r314", "r316", "r317" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Effective income tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r576", "r1037" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Income tax provision at statutory rate, percent", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r271", "r277", "r576", "r608", "r1037" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r580", "r1037", "r1170", "r1176", "r1257" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Non-taxable or non-deductible items, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r581", "r583", "r1170", "r1176", "r1257" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "State income taxes, net of federal benefit, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r579", "r1037", "r1170", "r1176", "r1257" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-unrecognized-tax-benefits-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Table]", "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation." } } }, "auth_ref": [ "r576", "r577", "r1037" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Changes in unrecognized tax benefits, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": [ "r582", "r1037", "r1170", "r1176", "r1257" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "negatedLabel": "Research and development credits, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1037", "r1170", "r1176", "r1257", "r1258" ] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet", "terseLabel": "Embedded Derivative, Fair Value of Embedded Derivative, Net", "documentation": "Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities." } } }, "auth_ref": [ "r1285", "r1286", "r1287" ] }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "terseLabel": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net", "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period." } } }, "auth_ref": [ "r1274", "r1280" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r548" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r548" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r545" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "terseLabel": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r152" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1093" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information", "http://www.tivichealth.com/20251231/role/statement-note-1-formation-and-business-of-the-company", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-tables", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-tables", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-tables", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-tables", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-tables", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-unrecognized-tax-benefits-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-tables", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-tables", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-tables", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-tables", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-tables", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-tables", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-tables", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-tables", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-tables", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-tables", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-tables", "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1093" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r1130" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1093" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1128" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1093" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1093" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1093" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1093" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1129" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityComponentDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r173", "r180", "r181", "r211", "r212", "r213", "r283", "r284", "r285", "r288", "r297", "r300", "r302", "r320", "r372", "r375", "r402", "r466", "r490", "r552", "r603", "r604", "r618", "r619", "r620", "r623", "r695", "r696", "r710", "r712", "r713", "r714", "r715", "r717", "r718", "r719", "r720", "r721", "r730", "r771", "r772", "r773", "r774", "r775", "r776", "r780", "r782", "r802", "r839", "r859", "r860", "r861", "r883", "r951" ] }, "tivc_EquityIssuableMaximumAggregateStatedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumAggregateStatedValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumAggregateStatedValue", "terseLabel": "Equity Issuable, Maximum Aggregate Stated Value", "documentation": "The maximum aggregate stated value of the issuable equity." } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumNumberOfShares", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumNumberOfShares", "terseLabel": "Equity Issuable, Maximum Number of Shares (in shares)", "documentation": "Equity Issuable, Maximum Number of Shares" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumNumberOfSharesTrancheFive": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumNumberOfSharesTrancheFive", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumNumberOfSharesTrancheFive", "terseLabel": "Equity Issuable, Maximum Number of Shares, Tranche Five (in shares)", "documentation": "Equity Issuable, Maximum Number of Shares, Tranche Five" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumNumberOfSharesTrancheFour": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumNumberOfSharesTrancheFour", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumNumberOfSharesTrancheFour", "terseLabel": "Equity Issuable, Maximum Number of Shares, Tranche Four (in shares)", "documentation": "Equity Issuable, Maximum Number of Shares, Tranche Four" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumNumberOfSharesTrancheOne": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumNumberOfSharesTrancheOne", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumNumberOfSharesTrancheOne", "terseLabel": "Equity Issuable, Maximum Number of Shares, Tranche One (in shares)", "documentation": "Equity Issuable, Maximum Number of Shares, Tranche One" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumNumberOfSharesTrancheSix": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumNumberOfSharesTrancheSix", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumNumberOfSharesTrancheSix", "terseLabel": "Equity Issuable, Maximum Number of Shares, Tranche Six (in shares)", "documentation": "Equity Issuable, Maximum Number of Shares, Tranche Six" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumNumberOfSharesTrancheThree": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumNumberOfSharesTrancheThree", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumNumberOfSharesTrancheThree", "terseLabel": "Equity Issuable, Maximum Number of Shares, Tranche Three (in shares)", "documentation": "Equity Issuable, Maximum Number of Shares, Tranche Three" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumNumberOfSharesTrancheTwo": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumNumberOfSharesTrancheTwo", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumNumberOfSharesTrancheTwo", "terseLabel": "Equity Issuable, Maximum Number of Shares, Tranche Two (in shares)", "documentation": "Equity Issuable, Maximum Number of Shares, Tranche Two" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumPercentOfSharesOwnable": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumPercentOfSharesOwnable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumPercentOfSharesOwnable", "terseLabel": "Equity Issuable, Maximum Percent of Shares Ownable", "documentation": "Maximum percent of shares ownable in the issuance of equity." } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumValue", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumValue", "terseLabel": "Equity Issuable, Maximum Value", "documentation": "Equity Issuable, Maximum Value" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumValueOfSharesTrancheFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumValueOfSharesTrancheFive", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumValueOfSharesTrancheFive", "terseLabel": "Equity Issuable, Maximum Value of Shares, Tranche Five", "documentation": "Equity Issuable, Maximum Value of Shares, Tranche Five" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumValueOfSharesTrancheFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumValueOfSharesTrancheFour", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumValueOfSharesTrancheFour", "terseLabel": "Equity Issuable, Maximum Value of Shares, Tranche Four", "documentation": "Equity Issuable, Maximum Value of Shares, Tranche Four" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumValueOfSharesTrancheOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumValueOfSharesTrancheOne", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumValueOfSharesTrancheOne", "terseLabel": "Equity Issuable, Maximum Value of Shares, Tranche One", "documentation": "Equity Issuable, Maximum Value of Shares, Tranche One" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumValueOfSharesTrancheSix": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumValueOfSharesTrancheSix", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumValueOfSharesTrancheSix", "terseLabel": "Equity Issuable, Maximum Value of Shares, Tranche Six", "documentation": "Equity Issuable, Maximum Value of Shares, Tranche Six" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumValueOfSharesTrancheThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumValueOfSharesTrancheThree", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumValueOfSharesTrancheThree", "terseLabel": "Equity Issuable, Maximum Value of Shares, Tranche Three", "documentation": "Equity Issuable, Maximum Value of Shares, Tranche Three" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumValueOfSharesTrancheTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumValueOfSharesTrancheTwo", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumValueOfSharesTrancheTwo", "terseLabel": "Equity Issuable, Maximum Value of Shares, Tranche Two", "documentation": "Equity Issuable, Maximum Value of Shares, Tranche Two" } } }, "auth_ref": [] }, "tivc_EquityIssuableMaximumValueTranchedFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMaximumValueTranchedFinancing", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMaximumValueTranchedFinancing", "terseLabel": "Equity Issuable, Maximum Value, Tranched Financing", "documentation": "Equity Issuable, Maximum Value, Tranched Financing" } } }, "auth_ref": [] }, "tivc_EquityIssuableMinimumPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMinimumPricePerShare", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMinimumPricePerShare", "terseLabel": "Equity Issuable, Minimum Price per Share (in dollars per share)", "documentation": "The minimum price per share of issuable equity." } } }, "auth_ref": [] }, "tivc_EquityIssuableMinimumSharesOutstandingForFirstRefusal": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableMinimumSharesOutstandingForFirstRefusal", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableMinimumSharesOutstandingForFirstRefusal", "terseLabel": "Equity Issuable, Minimum Shares Outstanding for First Refusal (in shares)", "documentation": "The minimum number of shares outstanding that will allow preferred offering investors first refusal." } } }, "auth_ref": [] }, "tivc_EquityIssuablePricePerSharePercentOfOnedayVwap": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuablePricePerSharePercentOfOnedayVwap", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuablePricePerSharePercentOfOnedayVwap", "terseLabel": "Equity Issuable, Price per Share, Percent of One-day VWAP", "documentation": "The purchase price per share of issuable equity, as a percent of one-day VWAP." } } }, "auth_ref": [] }, "tivc_EquityIssuablePricePerSharePercentOfThreedayVwap": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuablePricePerSharePercentOfThreedayVwap", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuablePricePerSharePercentOfThreedayVwap", "terseLabel": "Equity Issuable, Price per Share, Percent of Three-day VWAP", "documentation": "The price per share of issuable equity, as a percent of three-day VWAP." } } }, "auth_ref": [] }, "tivc_EquityIssuableTotalMaximumSharesOwnable": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableTotalMaximumSharesOwnable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableTotalMaximumSharesOwnable", "terseLabel": "Equity Issuable, Total Maximum Shares Ownable (in shares)", "documentation": "The total maximum shares ownable." } } }, "auth_ref": [] }, "tivc_EquityIssuableTotalMaximumSharesOwnablePercentOfOutstandingStock": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "EquityIssuableTotalMaximumSharesOwnablePercentOfOutstandingStock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_EquityIssuableTotalMaximumSharesOwnablePercentOfOutstandingStock", "terseLabel": "Equity Issuable, Total Maximum Shares Ownable, Percent of Outstanding Stock", "documentation": "The total maximum shares ownable, as a percent of outstanding stock." } } }, "auth_ref": [] }, "us-gaap_ErrorCorrectionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ErrorCorrectionTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements" ], "lang": { "en-us": { "role": { "label": "Error Correction [Text Block]", "documentation": "The entire disclosure for reporting error correction." } } }, "auth_ref": [ "r298" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r449", "r759", "r761", "r766", "r985", "r1020", "r1021" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r736", "r737", "r738", "r1038", "r1045", "r1061" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r736", "r737", "r1061" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r760", "r763", "r985", "r1065", "r1292" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r449", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r733", "r735", "r736", "r737", "r738", "r747", "r749", "r751", "r759", "r807", "r808", "r809", "r985", "r1020", "r1021", "r1026", "r1027", "r1028", "r1029", "r1030", "r1057", "r1061", "r1065" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r739", "r740", "r741", "r742", "r743", "r744", "r750" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r449", "r759", "r761", "r762", "r766", "r767", "r768", "r985", "r1020", "r1021", "r1292" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r734", "r735", "r736", "r738", "r1057", "r1286", "r1290" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r736", "r743", "r745", "r746", "r747", "r751", "r752", "r753", "r754", "r755", "r816", "r1057", "r1062" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r449", "r500", "r505", "r506", "r735", "r749", "r759", "r807", "r985", "r1026", "r1027", "r1028", "r1029", "r1030", "r1057", "r1065" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r449", "r500", "r505", "r506", "r508", "r735", "r736", "r749", "r759", "r808", "r985", "r1020", "r1021", "r1026", "r1027", "r1028", "r1029", "r1030", "r1057", "r1065" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r449", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r735", "r736", "r737", "r738", "r749", "r759", "r809", "r985", "r1020", "r1021", "r1026", "r1027", "r1028", "r1029", "r1030", "r1057", "r1061", "r1065" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r739", "r740", "r741", "r742", "r743", "r744", "r750" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r739", "r740", "r741", "r742", "r743", "r744", "r750" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r739", "r744", "r750" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r734", "r735", "r736", "r738", "r1057", "r1286", "r1290" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r1288", "r1289" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Net change in fair value", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r740", "r750" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Issuances", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r742", "r748", "r750" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r739", "r750" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r449", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r733", "r735", "r736", "r737", "r738", "r747", "r749", "r751", "r759", "r807", "r808", "r809", "r985", "r1020", "r1021", "r1026", "r1027", "r1028", "r1029", "r1030", "r1057", "r1061", "r1065" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r1057", "r1283", "r1284", "r1285", "r1286", "r1287", "r1290" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r1291" ] }, "tivc_FilingOfBlaWithFdaForAcuteRadiationSyndromeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "FilingOfBlaWithFdaForAcuteRadiationSyndromeMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Filing of BLA with FDA for Acute Radiation Syndrome [Member]", "documentation": "The filing of BLA with the FDA for Acute Radiation Syndrome." } } }, "auth_ref": [] }, "tivc_FirstTrancheInvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "FirstTrancheInvestorWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "First Tranche Investor Warrants [Member]", "documentation": "Relating to first tranche investor warrants." } } }, "auth_ref": [] }, "tivc_FourthTrancheClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "FourthTrancheClosingMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Fourth Tranche Closing [Member]", "documentation": "Represents the fourth tranche closing." } } }, "auth_ref": [] }, "tivc_FourthTrancheClosingPlacementAgentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "FourthTrancheClosingPlacementAgentServicesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Fourth Tranche Closing, Placement Agent Services [Member]", "documentation": "Stock sold during the fourth tranche closing, as payment for placement agent services." } } }, "auth_ref": [] }, "tivc_FourthTrancheInvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "FourthTrancheInvestorWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Fourth Tranche Investor Warrants [Member]", "documentation": "Relating to the fourth tranche investor warrants." } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 }, "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Change in fair value of derivative liability", "negatedLabel": "Change in fair value of derivative liability", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r1275" ] }, "us-gaap_GainLossOnTerminationOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnTerminationOfLease", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnTerminationOfLease", "terseLabel": "Gain (Loss) on Termination of Lease", "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term." } } }, "auth_ref": [ "r783" ] }, "tivc_GoingConcernUncertaintyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "GoingConcernUncertaintyPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Going Concern Uncertainty [Policy Text Block]", "documentation": "The going concern uncertainty policy." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 }, "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r197", "r382", "r817", "r1012", "r1018", "r1038", "r1042", "r1043", "r1054", "r1058", "r1076", "r1201", "r1202", "r1269" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r381", "r392", "r1018" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GranteeStatusAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r512", "r514", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r540", "r541", "r542", "r543", "r544" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GranteeStatusDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r512", "r514", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r540", "r541", "r542", "r543", "r544" ] }, "tivc_HaywardCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "HaywardCaliforniaMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Hayward California [Member]", "documentation": "Represent Hayward California." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1095", "r1096", "r1109" ] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf", "terseLabel": "Impairment of Long-Lived Assets to be Disposed of", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r9", "r112", "r1059" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r118" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r271", "r276", "r575" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r271", "r276", "r575" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 }, "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Net loss from continuing operations", "totalLabel": "Net loss from operations before discontinued operations", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r133", "r144", "r181", "r271", "r274", "r275", "r287", "r297", "r371", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r467", "r552", "r622", "r696", "r732", "r767", "r836", "r1005", "r1187", "r1189", "r1190", "r1191", "r1192", "r1214" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: net loss from discontinued operations", "label": "Loss from discontinued operations", "totalLabel": "Net loss from discontinued operations", "terseLabel": "Loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r62", "r63", "r64", "r65", "r66", "r76", "r190", "r612", "r837" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r405", "r406", "r1031", "r1032" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-tables" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r14", "r18", "r22", "r58", "r67", "r68", "r69", "r70", "r71", "r75", "r77", "r78", "r117", "r405", "r406" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r403", "r412", "r414", "r702", "r703", "r704", "r705", "r740", "r744", "r750", "r768", "r769", "r770", "r854", "r856", "r936", "r983", "r985", "r1038", "r1043", "r1055", "r1056", "r1060", "r1065", "r1262", "r1264", "r1316" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r412", "r414", "r702", "r703", "r704", "r705", "r740", "r744", "r750", "r768", "r769", "r770", "r854", "r856", "r936", "r983", "r985", "r1038", "r1043", "r1055", "r1056", "r1060", "r1065", "r1262", "r1264", "r1316" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r267", "r576", "r577", "r588", "r600", "r1037", "r1260" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r267", "r576", "r577", "r588", "r600", "r1037", "r1260" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r271", "r277", "r570", "r576", "r584", "r585", "r586", "r591", "r598", "r609", "r611", "r613", "r614", "r824", "r870", "r882", "r1037" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "totalLabel": "Effective income tax rate, amount", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r147", "r155", "r271", "r301", "r302", "r319", "r339", "r360", "r574", "r576", "r610", "r841", "r995", "r997", "r999", "r1037" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r210", "r572", "r573", "r591", "r592", "r597", "r602", "r876" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r580", "r1037", "r1257" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Income tax provision at statutory rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r576", "r1037" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Non-taxable or non-deductible items", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r581", "r583", "r1257" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "State income taxes, net of federal benefit", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r579", "r1037", "r1257" ] }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationTaxContingencies", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Changes in unrecognized tax benefits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies." } } }, "auth_ref": [ "r582", "r1037", "r1257" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxReconciliationTaxCreditsResearch", "negatedLabel": "Research and development credits", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1037", "r1257", "r1258" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxesPaidNet", "terseLabel": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r29", "r267", "r599", "r600" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedTerseLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedTerseLabel": "Convertible note issued in exchange for purchase of Scorpius assets and goodwill", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r1137", "r1167" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherOperatingAssets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedTerseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r1113" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1097", "r1116" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "ecd_InsiderTrdPoliciesProcAdoptedFlag", "terseLabel": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1097", "r1116" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Licensed technology, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r394", "r1203", "r1204" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 0.0 }, "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseNonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r335", "r995", "r999", "r1164" ] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryCurrentTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-tables" ], "lang": { "en-us": { "role": { "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r377" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1148" ] }, "tivc_InventoryFinishedGoodsAndWorkInProcessMassNet": { "xbrltype": "massItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "InventoryFinishedGoodsAndWorkInProcessMassNet", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_InventoryFinishedGoodsAndWorkInProcessMassNet", "terseLabel": "Inventory, Finished Goods and Work in Process, Mass, Net (Kilogram)", "documentation": "The mass of work in process and finished inventory." } } }, "auth_ref": [] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryGross", "totalLabel": "Inventory at cost", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryNet", "totalLabel": "Total Inventory, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r204", "r987", "r1076" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r148", "r193", "r203", "r377", "r378", "r380", "r814", "r1001" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1150" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryValuationReserves", "terseLabel": "Inventory Valuation Reserves", "negatedLabel": "Less: reserve for obsolescence", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r110", "r1152" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1149" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryWriteDown", "terseLabel": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r379" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r319", "r334", "r360", "r1011", "r1163" ] }, "tivc_InvestorRightToParticipateInFinancingPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "InvestorRightToParticipateInFinancingPercent", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_InvestorRightToParticipateInFinancingPercent", "terseLabel": "Investor Right to Participate in Financing, Percent", "documentation": "The maximum percent that investors can participate in financing." } } }, "auth_ref": [] }, "tivc_InvestorRightToUseFinancingToRedeemSharesPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "InvestorRightToUseFinancingToRedeemSharesPercent", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_InvestorRightToUseFinancingToRedeemSharesPercent", "terseLabel": "Investor Right to Use Financing to Redeem Shares, Percent", "documentation": "The maximum percent that investors may use financing proceeds to redeem shares." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims", "terseLabel": "Issuance of warrants for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r9" ] }, "tivc_IssuanceOfStockForEquityLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "IssuanceOfStockForEquityLineOfCreditMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Issuance of Stock for Equity Line of Credit [Member]", "documentation": "The issuance of stock for an equity line of credit." } } }, "auth_ref": [] }, "tivc_IssuanceOfStockInExchangeForLicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "IssuanceOfStockInExchangeForLicenseMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Issuance of Stock in Exchange for License [Member]", "documentation": "The issuance of stock in exchange for licenses." } } }, "auth_ref": [] }, "tivc_IssuanceOfWarrantsForDiscountRelatedPartyConvertibleNotePayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "IssuanceOfWarrantsForDiscountRelatedPartyConvertibleNotePayableMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Issuance of Warrants for Discount Related Party Convertible Note Payable [Member]", "documentation": "Represents the issuance of warrants in exchange for discount related party convertible note payable." } } }, "auth_ref": [] }, "tivc_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LabEquipmentMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Lab Equipment [Member]", "documentation": "Lab Equipment" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r793", "r1136" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r793", "r1136" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r787", "r1067" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1298" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information", "http://www.tivichealth.com/20251231/role/statement-note-1-formation-and-business-of-the-company", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-tables", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-tables", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-tables", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-tables", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-tables", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-unrecognized-tax-benefits-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-tables", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-tables", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-tables", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-tables", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-tables", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-tables", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-tables", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-tables", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-tables", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-tables", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-tables", "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LegalFees", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LegalFees", "terseLabel": "Legal Fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r1141", "r1349", "r1350" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r786" ] }, "tivc_LesseeOperatingLeaseAnnualLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LesseeOperatingLeaseAnnualLeasePayments", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_LesseeOperatingLeaseAnnualLeasePayments", "terseLabel": "Lessee, Operating Lease, Annual Lease Payments", "documentation": "The annual amount of lease payments on the operating lease." } } }, "auth_ref": [] }, "tivc_LesseeOperatingLeaseAnnualRentIncreasePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LesseeOperatingLeaseAnnualRentIncreasePercentage", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_LesseeOperatingLeaseAnnualRentIncreasePercentage", "terseLabel": "Lessee, Operating Lease, Annual Rent Increase, Percentage", "documentation": "Represents the annual rent increase percentage for an operating lease." } } }, "auth_ref": [] }, "tivc_LesseeOperatingLeaseBaseRent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LesseeOperatingLeaseBaseRent", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_LesseeOperatingLeaseBaseRent", "terseLabel": "Lessee, Operating Lease, Base Rent", "documentation": "Represents the base rent of an operating lease." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r791", "r1171", "r1177", "r1312" ] }, "tivc_LesseeOperatingLeaseMonthlyRentPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LesseeOperatingLeaseMonthlyRentPayments", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_LesseeOperatingLeaseMonthlyRentPayments", "terseLabel": "Lessee, Operating Lease, Monthly Rent Payments", "documentation": "Monthly rental payments on the operating lease." } } }, "auth_ref": [] }, "tivc_LesseeOperatingLeaseOptionToPurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LesseeOperatingLeaseOptionToPurchaseAmount", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_LesseeOperatingLeaseOptionToPurchaseAmount", "terseLabel": "Lessee, Operating Lease, Option to Purchase, Amount", "documentation": "Represents the purchase price option of an operating lease." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1297" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1297" ] }, "tivc_LessorOperatingLeaseAnnualRentIncreasePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LessorOperatingLeaseAnnualRentIncreasePercentage", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_LessorOperatingLeaseAnnualRentIncreasePercentage", "terseLabel": "Lessor, Operating Lease, Annual Rent Increase, Percentage", "documentation": "Represents the annual rent increase percentage of an operating lease." } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "terseLabel": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r794" ] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LessorOperatingLeaseTermOfContract", "terseLabel": "Lessor, Operating Lease, Term of Contract (Month)", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1299" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r20", "r80", "r81", "r82", "r85", "r86", "r87", "r90", "r271", "r274", "r275", "r371", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r699", "r700", "r701", "r767", "r911", "r1004", "r1024", "r1091", "r1214", "r1303", "r1304" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r98", "r140", "r832", "r1076", "r1079", "r1080", "r1170", "r1175", "r1198", "r1293" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r82", "r192", "r271", "r274", "r275", "r371", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r699", "r700", "r701", "r767", "r1076", "r1214", "r1303", "r1304" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesFairValueDisclosure", "terseLabel": "Total liabilities", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r735", "r1283" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details" ], "lang": { "en-us": { "role": { "label": "Current liabilities of discontinued operations", "totalLabel": "Total current liabilities of discontinued operations", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r58", "r74", "r113", "r116", "r189", "r190" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities of discontinued operations", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r3", "r58", "r74", "r116", "r189", "r190" ] }, "tivc_LicenseAgreementMaximumLienPayoffAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LicenseAgreementMaximumLienPayoffAmount", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_LicenseAgreementMaximumLienPayoffAmount", "terseLabel": "License Agreement, Maximum Lien Payoff Amount", "documentation": "License Agreement, Maximum Lien Payoff Amount" } } }, "auth_ref": [] }, "tivc_LicenseAgreementMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LicenseAgreementMilestonePayments", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "tivc_LicenseAgreementMilestonePayments", "terseLabel": "Milestone payments", "documentation": "Milestone payments on the license agreement." } } }, "auth_ref": [] }, "tivc_LicenseAgreementPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LicenseAgreementPaymentPercentage", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_LicenseAgreementPaymentPercentage", "terseLabel": "Subordinated Debt, Percent Received", "documentation": "License Agreement, Payment Percentage" } } }, "auth_ref": [] }, "tivc_LicenseAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LicenseAgreementTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement" ], "lang": { "en-us": { "role": { "label": "License Agreement [Text Block]", "documentation": "Disclosure of the license agreement." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebt", "totalLabel": "Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r20", "r138", "r272", "r282", "r448", "r463", "r822", "r1020", "r1021", "r1066", "r1313" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r272", "r282", "r453", "r822" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "terseLabel": "2029", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r272", "r282", "r453", "r822" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "terseLabel": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r272", "r282", "r453", "r822" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r272", "r282", "r453", "r822" ] }, "us-gaap_LongTermPurchaseCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermPurchaseCommitmentTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-tables" ], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment [Table]", "documentation": "Disclosure of information about long-term purchase arrangement. Includes, but is not limited to, term of arrangement with supplier, minimum quantity required, milestone, period covered by arrangement, and committed amount. Excludes short-term purchase arrangement and unconditional purchase obligation." } } }, "auth_ref": [] }, "tivc_LongtermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "LongtermDebtMaturityAfterYearFour", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details" ], "lang": { "en-us": { "role": { "label": "tivc_LongtermDebtMaturityAfterYearFour", "terseLabel": "Thereafter", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LossContingencyAccrualAtCarryingValue", "terseLabel": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r419", "r1132" ] }, "tivc_MammalianBuildingLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "MammalianBuildingLeaseMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Mammalian Building Lease [Member]", "documentation": "Relating to the Mammalian Building Lease." } } }, "auth_ref": [] }, "tivc_ManufacturingToolsAndDiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ManufacturingToolsAndDiesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Manufacturing Tools and Dies [Member]", "documentation": "Manufacturing tools and dies." } } }, "auth_ref": [] }, "tivc_MastHillPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "MastHillPurchaseAgreementMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Mast Hill Purchase Agreement [Member]", "documentation": "The Mast Hill Purchase Agreement." } } }, "auth_ref": [] }, "tivc_MaximMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "MaximMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Maxim [Member]", "documentation": "Maxim." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r169", "r170", "r326", "r420", "r421", "r422", "r423", "r509", "r541", "r542", "r543", "r566", "r738", "r813", "r853", "r855", "r869", "r903", "r904", "r954", "r956", "r959", "r960", "r968", "r975", "r976", "r977", "r978", "r981", "r982", "r1017", "r1025", "r1033", "r1038", "r1045", "r1048", "r1061", "r1062", "r1063", "r1064", "r1077", "r1216", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310" ] }, "tivc_MaximumPercentageOfNetProceedsFromEquityFinancingToRedeemPreferredStock": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "MaximumPercentageOfNetProceedsFromEquityFinancingToRedeemPreferredStock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_MaximumPercentageOfNetProceedsFromEquityFinancingToRedeemPreferredStock", "terseLabel": "Maximum Percentage of Net Proceeds from Equity Financing to Redeem Preferred Stock", "documentation": "The maximum percent of net proceeds from equity financing that may be used to redeem preferred stock." } } }, "auth_ref": [] }, "tivc_MaximumReimbursementExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "MaximumReimbursementExpenses", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_MaximumReimbursementExpenses", "terseLabel": "Maximum Reimbursement Expenses", "documentation": "Maximum Reimbursement Expenses" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r542", "r1285", "r1286", "r1287" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r540", "r1285", "r1286", "r1287" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r541", "r1061", "r1285", "r1286", "r1287" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r543", "r1285", "r1286", "r1287" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r539", "r540", "r541", "r542", "r543", "r544", "r736", "r737", "r738", "r1038", "r1045", "r1048", "r1061" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r736", "r737", "r738", "r1038", "r1045", "r1048", "r1061" ] }, "tivc_MicrobialBuildingLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "MicrobialBuildingLeaseMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Microbial Building Lease [Member]", "documentation": "Relating to the Microbial Building Lease." } } }, "auth_ref": [] }, "tivc_Milestone1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "Milestone1Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Milestone 1 [Member]", "documentation": "The first milestone." } } }, "auth_ref": [] }, "tivc_Milestone2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "Milestone2Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Milestone 2 [Member]", "documentation": "The second milestone." } } }, "auth_ref": [] }, "tivc_Milestone3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "Milestone3Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Milestone 3 [Member]", "documentation": "The third milestone." } } }, "auth_ref": [] }, "tivc_Milestone4Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "Milestone4Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Milestone 4 [Member]", "documentation": "The fourth milestone." } } }, "auth_ref": [] }, "tivc_Milestone5Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "Milestone5Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Milestone 5 [Member]", "documentation": "The fifth milestone." } } }, "auth_ref": [] }, "tivc_Milestone6Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "Milestone6Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Milestone 6 [Member]", "documentation": "The sixth milestone." } } }, "auth_ref": [] }, "tivc_Milestone7Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "Milestone7Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Milestone 7 [Member]", "documentation": "The seventh milestone." } } }, "auth_ref": [] }, "tivc_Milestone8Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "Milestone8Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Milestone 8 [Member]", "documentation": "The eighth milestone." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r169", "r170", "r326", "r420", "r421", "r422", "r423", "r509", "r541", "r542", "r543", "r566", "r738", "r813", "r853", "r855", "r869", "r903", "r904", "r954", "r956", "r959", "r960", "r968", "r975", "r976", "r977", "r978", "r981", "r982", "r1017", "r1025", "r1033", "r1038", "r1045", "r1048", "r1061", "r1062", "r1063", "r1077", "r1216", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1226", "r1227" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1114" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r266" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r266" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "terseLabel": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r106", "r107", "r108" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "totalLabel": "Net cash used in operating activities - continuing operations", "documentation": "Amount of cash inflow (outflow) from operating activity attributable to continuing operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r106", "r107", "r108" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details": { "parentTag": "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic", "weight": 1.0, "order": 0.0 }, "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Net loss", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r102", "r108", "r141", "r181", "r190", "r208", "r209", "r213", "r271", "r274", "r275", "r279", "r287", "r292", "r293", "r295", "r296", "r297", "r301", "r302", "r308", "r371", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r467", "r470", "r473", "r479", "r552", "r622", "r696", "r732", "r767", "r838", "r932", "r949", "r950", "r995", "r997", "r999", "r1089", "r1214" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r263", "r264", "r265", "r286", "r287", "r288", "r289", "r290", "r291", "r295", "r303", "r318", "r368", "r369", "r372", "r373", "r374", "r375", "r401", "r402", "r413", "r464", "r465", "r466", "r467", "r550", "r551", "r552", "r553", "r603", "r604", "r605", "r606", "r607", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r669", "r670", "r671", "r692", "r693", "r694", "r695", "r696", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r756", "r757", "r780", "r781", "r797", "r798", "r799", "r800", "r801", "r802", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r874" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1114" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1114" ] }, "tivc_NoncashInvestingAndFinancingActivitiesDeemedDividendsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "NoncashInvestingAndFinancingActivitiesDeemedDividendsAmount", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Deemed dividends", "documentation": "Represents the amount of deemed dividends reported under noncash investing and financing activities during the period." } } }, "auth_ref": [] }, "tivc_NoncashInvestingAndFinancingActivitiesDividendsDeclaredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "NoncashInvestingAndFinancingActivitiesDividendsDeclaredAmount", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Dividends declared", "documentation": "Represents the amount of dividends declared reported under noncash investing and financing activities during the period." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure on non-cash financing activities" } } }, "auth_ref": [] }, "tivc_NoncashWriteoffOfRouAssetsAndLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "NoncashWriteoffOfRouAssetsAndLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Write-off of ROU asset and lease liability", "documentation": "The non-cash write-off of ROU assets and lease liabilities." } } }, "auth_ref": [] }, "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonmonetaryTransactionTypeAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Axis]", "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r795", "r796", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075" ] }, "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonmonetaryTransactionTypeDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Domain]", "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r795", "r796", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 }, "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Net other (expense) income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r104" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "OTHER (EXPENSE) INCOME" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-tables" ], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r19" ] }, "tivc_NoteOfferingWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "NoteOfferingWarrantMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Note Offering Warrant [Member]", "documentation": "Note Offering Warrant" } } }, "auth_ref": [] }, "tivc_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "tivc_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1012", "r1188" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1006", "r1016", "r1188" ] }, "tivc_OfficeSubleaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "OfficeSubleaseMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Office Sublease [Member]", "documentation": "Relating to the Office Sublease." } } }, "auth_ref": [] }, "us-gaap_OpenTaxYear": { "xbrltype": "gYearListItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OpenTaxYear", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OpenTaxYear", "terseLabel": "Open Tax Year", "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format." } } }, "auth_ref": [ "r588" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 }, "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ "r999" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r144", "r995", "r999", "r1005", "r1187", "r1189", "r1190", "r1191", "r1192" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r788", "r1067" ] }, "tivc_OperatingLeaseImplicitRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "OperatingLeaseImplicitRatePercent", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_OperatingLeaseImplicitRatePercent", "terseLabel": "Operating Lease, Implicit Rate, Percent", "documentation": "Represent implicit rate." } } }, "auth_ref": [] }, "tivc_OperatingLeaseIncrementalBorrowingRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "OperatingLeaseIncrementalBorrowingRatePercent", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_OperatingLeaseIncrementalBorrowingRatePercent", "terseLabel": "Operating Lease, Incremental Borrowing Rate, Percent", "documentation": "Represent Incremental Borrowing Rate." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseLiability", "terseLabel": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r784" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeasePayments", "terseLabel": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r785", "r790" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of right-of-use asset", "label": "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1168" ] }, "tivc_OperatingLeaseTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "OperatingLeaseTerminationFee", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_OperatingLeaseTerminationFee", "terseLabel": "Operating Lease Termination Fee", "documentation": "Amount of Operating Lease Termination Fee." } } }, "auth_ref": [] }, "tivc_OperatingLossCarryforwardsCanBeCarriedForwardIndefinitely": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "OperatingLossCarryforwardsCanBeCarriedForwardIndefinitely", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_OperatingLossCarryforwardsCanBeCarriedForwardIndefinitely", "terseLabel": "Operating Loss Carryforwards, Can be Carried Forward Indefinitely", "documentation": "Amount of Operating Loss Carryforwards, Can be Carried Forward Indefinitely." } } }, "auth_ref": [] }, "tivc_OperatingLossCarryforwardsCanBeUtilizedEachYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "OperatingLossCarryforwardsCanBeUtilizedEachYear", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_OperatingLossCarryforwardsCanBeUtilizedEachYear", "terseLabel": "Operating Loss Carryforwards, Can be Utilized Each Year", "documentation": "The amount of operating loss carryforwards that can be utilized each year." } } }, "auth_ref": [] }, "tivc_OperatingLossCarryforwardsIncurredPriorToOwnershipChange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "OperatingLossCarryforwardsIncurredPriorToOwnershipChange", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_OperatingLossCarryforwardsIncurredPriorToOwnershipChange", "terseLabel": "Operating Loss Carryforwards, Incurred Prior to Ownership Change", "documentation": "Amount of operating loss carryforward, before tax effects and prior to ownership change, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [] }, "tivc_OperatingLossCarryforwardsSubjectToExpire": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "OperatingLossCarryforwardsSubjectToExpire", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_OperatingLossCarryforwardsSubjectToExpire", "terseLabel": "Operating Loss Carryforwards, Subject to Expire", "documentation": "Amount of Operating Loss Carryforwards, Subject to Expire." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-1-formation-and-business-of-the-company" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r132", "r182", "r184", "r186", "r872", "r873" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Other accrued expenses", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "terseLabel": "Total Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r81" ] }, "tivc_OtherAccruedLiabilitiesOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "OtherAccruedLiabilitiesOtherCurrent", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "tivc_OtherAccruedLiabilitiesOtherCurrent", "terseLabel": "Other", "documentation": "Other accrued liabilities that have been doubly classified as other." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r198" ] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCommitmentsTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other non-current liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r86" ] }, "tivc_OwnershipOfStockOptionGrants": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "OwnershipOfStockOptionGrants", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_OwnershipOfStockOptionGrants", "terseLabel": "Ownership of Stock, Option Grants", "documentation": "The ownership percent of stock after option grants." } } }, "auth_ref": [] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Non-cash interest expense", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9" ] }, "tivc_ParentOrSubsidiaryOfCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ParentOrSubsidiaryOfCompanyMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Parent or Subsidiary of Company [Member]", "documentation": "A parent or subsidiary of the company." } } }, "auth_ref": [] }, "us-gaap_PaymentsForCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsForCommissions", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForCommissions", "terseLabel": "Payments for Commissions", "documentation": "The amount of cash paid for commissions during the current period." } } }, "auth_ref": [ "r7" ] }, "tivc_PaymentsForServicesCashFee": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PaymentsForServicesCashFee", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_PaymentsForServicesCashFee", "terseLabel": "Payments for Services, Cash Fee", "documentation": "The cash fee payable, as a percent of funds received from investors." } } }, "auth_ref": [] }, "tivc_PaymentsForServicesValueOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PaymentsForServicesValueOfCommonStockPercent", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_PaymentsForServicesValueOfCommonStockPercent", "terseLabel": "Payments for Services, Value of Common Stock, Percent", "documentation": "The value of common stock issued from warrant exercises, as a percent of the value of funds received from investors." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Issuance costs in connection with senior convertible note", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r26" ] }, "tivc_PaymentsOfRefundsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PaymentsOfRefundsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "tivc_PaymentsOfRefundsOfStockIssuanceCosts", "negatedLabel": "Offering costs in advance of sale of common stock", "documentation": "The cash outflow (inflow) for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [] }, "tivc_PaymentsOfReimbursementOfExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PaymentsOfReimbursementOfExpenses", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_PaymentsOfReimbursementOfExpenses", "terseLabel": "Payments of Reimbursement of Expenses", "documentation": "Payments of Reimbursement of Expenses" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfStockIssuanceCosts", "terseLabel": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r25" ] }, "tivc_PaymentsOfStockIssuanceCostsFractionalShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PaymentsOfStockIssuanceCostsFractionalShares", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_PaymentsOfStockIssuanceCostsFractionalShares", "terseLabel": "Payments of Stock Issuance Costs, Fractional Shares", "documentation": "The payments of stock issuance costs, in relation to the issuance of fractional shares." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireIntangibleAssets", "negatedLabel": "Acquisition of licensed technology", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r105" ] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireNotesReceivable", "negatedLabel": "Issuance of note receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [ "r23" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireProductiveAssets", "terseLabel": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r146", "r1271", "r1272", "r1273" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Acquisition of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r105" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PlanNameDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253" ] }, "tivc_PolicyTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PolicyTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "tivc_PolicyTable" } } }, "auth_ref": [] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r758", "r759", "r761", "r762", "r766", "r767", "r768", "r985", "r1292" ] }, "tivc_PotentialDevelopmentMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PotentialDevelopmentMilestonesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Potential Development Milestones [Member]", "documentation": "Potential Development Milestones." } } }, "auth_ref": [] }, "tivc_PreferredPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PreferredPurchaseAgreementMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred Purchase Agreement [Member]", "documentation": "The preferred purchase agreement." } } }, "auth_ref": [] }, "tivc_PreferredPurchaseAgreementPlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PreferredPurchaseAgreementPlacementAgentMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred Purchase Agreement, Placement Agent [Member]", "documentation": "Placement agent awards in the preferred purchase agreement." } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleConversionPrice", "terseLabel": "Preferred Stock, Convertible, Conversion Price (in dollars per share)", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r482" ] }, "tivc_PreferredStockConvertibleConversionPricePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PreferredStockConvertibleConversionPricePercent", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_PreferredStockConvertibleConversionPricePercent", "terseLabel": "Preferred Stock, Convertible, Conversion Price, Percent", "documentation": "The conversion price of the preferred stock, as the given percent equal to the lowest closing volume-weighted average price." } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockConvertibleConversionRatio", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleConversionRatio", "terseLabel": "Preferred Stock, Convertible, Conversion Ratio", "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted." } } }, "auth_ref": [ "r482" ] }, "tivc_PreferredStockConvertibleRedeemablePricePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PreferredStockConvertibleRedeemablePricePercent", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_PreferredStockConvertibleRedeemablePricePercent", "terseLabel": "Preferred Stock, Convertible, Redeemable Price, Percent", "documentation": "The redeemable price of the convertible preferred stock, as the given percent of the stated value." } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockDividendRatePercentage", "terseLabel": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r481", "r955", "r957", "r958", "r969" ] }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details": { "parentTag": "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockDividendsIncomeStatementImpact", "negatedTerseLabel": "Dividends on Preferred Stock", "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders." } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r1081", "r1082", "r1085", "r1086", "r1087", "r1088", "r1345", "r1351" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r92", "r480" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r92", "r913" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, issued (in shares)", "terseLabel": "Preferred Stock, Shares Issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r92", "r480" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, outstanding (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r92", "r913", "r931", "r1351", "r1352" ] }, "tivc_PreferredStockStatedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PreferredStockStatedValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_PreferredStockStatedValue", "terseLabel": "Preferred Stock, Stated Value", "documentation": "The stated value of a share of preferred stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Text Block]", "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock." } } }, "auth_ref": [ "r122", "r471" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 403 shares issued and outstanding as of December 31, 2025, and no shares issued and outstanding as of December 31, 2024", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r92", "r469", "r476", "r828", "r1076" ] }, "tivc_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PrefundedWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Prefunded Warrants [Member]", "documentation": "Prefunded Warrants" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1153" ] }, "tivc_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Policy Text Block]", "documentation": "The accounting policy for the prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromConvertibleDebt", "terseLabel": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock, net of issuance costs", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r4" ] }, "tivc_ProceedsFromIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock and warrants, net of issuance costs", "documentation": "The amount of cash inflow from the issuance of common stock and warrants, net of issuance costs." } } }, "auth_ref": [] }, "tivc_ProceedsFromIssuanceOfCommonStockNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ProceedsFromIssuanceOfCommonStockNet", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ProceedsFromIssuanceOfCommonStockNet", "terseLabel": "Proceeds from Issuance of Common Stock, Net", "documentation": "Proceeds from common stock, net." } } }, "auth_ref": [] }, "tivc_ProceedsFromIssuanceOfPreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ProceedsFromIssuanceOfPreferredStockAndWarrants", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of preferred stock and warrants, net of issuance costs", "documentation": "Proceeds from Issuance of Preferred Stock and Warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfWarrants", "terseLabel": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r4", "r877" ] }, "tivc_ProceedsFromIssuanceOrSaleOfEquityGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ProceedsFromIssuanceOrSaleOfEquityGross", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ProceedsFromIssuanceOrSaleOfEquityGross", "terseLabel": "Proceeds from Issuance or Sale of Equity, Gross", "documentation": "Proceeds from the issuance or sale of equity, before deducting offering costs." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from warrant exercises", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r1166" ] }, "tivc_ProfessionalFeesBringdown": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ProfessionalFeesBringdown", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_ProfessionalFeesBringdown", "terseLabel": "Professional Fees, Bringdown", "documentation": "Additional professional fees for each bringdown." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12", "r792" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r111", "r151", "r153", "r154" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentGross", "terseLabel": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r114", "r195", "r835" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Total Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r792", "r823", "r835", "r1076" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r12", "r151", "r153", "r833" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r114", "r792" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProvisionForDoubtfulAccounts", "terseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r215", "r229", "r376" ] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PublicUtilitiesInventoryAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": [ "r1151" ] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Inventory [Domain]", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, "auth_ref": [ "r1151" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r169", "r170", "r326", "r420", "r421", "r422", "r423", "r499", "r509", "r541", "r542", "r543", "r549", "r566", "r738", "r810", "r811", "r813", "r853", "r855", "r869", "r903", "r904", "r954", "r956", "r959", "r960", "r968", "r975", "r976", "r977", "r978", "r981", "r982", "r1017", "r1025", "r1033", "r1038", "r1045", "r1048", "r1061", "r1062", "r1063", "r1064", "r1077", "r1083", "r1211", "r1216", "r1286", "r1306", "r1307", "r1308", "r1309", "r1310" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r169", "r170", "r326", "r420", "r421", "r422", "r423", "r499", "r509", "r541", "r542", "r543", "r549", "r566", "r738", "r810", "r811", "r813", "r853", "r855", "r869", "r903", "r904", "r954", "r956", "r959", "r960", "r968", "r975", "r976", "r977", "r978", "r981", "r982", "r1017", "r1025", "r1033", "r1038", "r1045", "r1048", "r1061", "r1062", "r1063", "r1064", "r1077", "r1083", "r1211", "r1216", "r1286", "r1306", "r1307", "r1308", "r1309", "r1310" ] }, "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-tables" ], "lang": { "en-us": { "role": { "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Table]", "documentation": "Disclosure of information about reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets." } } }, "auth_ref": [ "r41", "r42" ] }, "tivc_RegisteredPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "RegisteredPublicOfferingMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Registered Public Offering [Member]", "documentation": "The registered public offering." } } }, "auth_ref": [] }, "tivc_RegisteredPublicOfferingPlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "RegisteredPublicOfferingPlacementAgentMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Registered Public Offering, Placement Agent [Member]", "documentation": "Placement agent awards in the registered public offering." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r166", "r167", "r271", "r280", "r281", "r439", "r483", "r803", "r812", "r825", "r989", "r991", "r992", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1276", "r1277", "r1278", "r1279" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r569", "r1256" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r569", "r1256" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 }, "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r568", "r983", "r995", "r996", "r1011", "r1311" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r567" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r1260" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RestatementAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r168", "r174", "r180", "r181", "r183", "r250", "r283", "r284", "r285", "r287", "r288", "r292", "r293", "r294", "r295", "r298", "r299", "r300", "r301", "r302", "r303", "r318", "r373", "r374", "r466", "r467", "r552", "r619", "r620", "r622", "r623", "r695", "r696", "r726", "r730", "r731", "r732", "r781", "r801", "r802", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r874", "r1193" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RestatementDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r168", "r174", "r180", "r181", "r183", "r250", "r283", "r284", "r285", "r287", "r288", "r292", "r293", "r294", "r295", "r298", "r299", "r300", "r301", "r302", "r303", "r318", "r373", "r374", "r466", "r467", "r552", "r619", "r620", "r622", "r623", "r695", "r696", "r726", "r730", "r731", "r732", "r781", "r801", "r802", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r874", "r1193" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r194" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedStockMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r1186", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [ "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r95", "r125", "r831", "r863", "r868", "r881", "r914", "r1076" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r173", "r180", "r181", "r283", "r284", "r285", "r288", "r297", "r300", "r302", "r372", "r375", "r402", "r466", "r552", "r603", "r604", "r618", "r619", "r620", "r623", "r695", "r696", "r710", "r713", "r714", "r717", "r730", "r780", "r782", "r859", "r861", "r883", "r1351" ] }, "tivc_ReturnsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ReturnsPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Returns [Policy Text Block]", "documentation": "The returns policy." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r156", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r984" ] }, "tivc_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ReverseStockSplitMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding." } } }, "auth_ref": [] }, "tivc_ReverseStockSplitPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ReverseStockSplitPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Policy Text Block]", "documentation": "The reverse stock split policy." } } }, "auth_ref": [] }, "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Error Correction, Adjustment [Member]", "documentation": "Cumulative increase (decrease) to previously issued financial statements for correction of error." } } }, "auth_ref": [ "r292", "r293", "r294", "r299", "r300", "r301", "r302" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1114" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1114" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioForecastMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r510", "r1142" ] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioPreviouslyReportedMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r174", "r180", "r181", "r283", "r285", "r287", "r288", "r292", "r293", "r302", "r318", "r466", "r467", "r552", "r619", "r622", "r623", "r695", "r696", "r726", "r730", "r731", "r781", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r874", "r1138", "r1139", "r1140", "r1181", "r1182", "r1193", "r1199", "r1200", "r1282", "r1300", "r1301" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r168", "r185", "r187", "r303", "r510", "r1132" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-tables" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r314" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-tables" ], "lang": { "en-us": { "role": { "label": "Business Combination [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r393", "r627", "r628", "r629", "r630", "r636", "r637", "r638", "r639", "r645", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r663", "r664", "r665", "r666", "r667", "r673", "r674", "r675", "r676", "r677", "r678", "r684", "r685", "r686", "r690", "r1038", "r1048", "r1263", "r1265", "r1267" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r20", "r49", "r52", "r56", "r123", "r124", "r1020", "r1022", "r1171", "r1177", "r1295", "r1312" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1259" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-tables" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r14", "r18", "r22", "r58", "r67", "r68", "r69", "r70", "r71", "r75", "r77", "r78", "r117", "r1205", "r1206" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1185" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r578", "r1037", "r1257" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r54" ] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-tables" ], "lang": { "en-us": { "role": { "label": "Error Correction [Table]", "documentation": "Disclosure of information about prior period adjustment to correct error in previously issued financial statement. Includes, but is not limited to, effect of correction on financial statement line item, affected per-share amount, cumulative effect of change on retained earnings and other appropriate component of equity or net assets in statement of financial position, and effect of prior period adjustment on net income of each prior period presented." } } }, "auth_ref": [ "r292", "r293", "r294", "r299", "r300", "r301", "r302", "r318" ] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": [ "r33", "r34", "r35" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r11", "r99", "r100", "r101" ] }, "tivc_ScheduleOfMilestonePaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ScheduleOfMilestonePaymentsTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Milestone Payments [Table Text Block]", "documentation": "Tabular disclosure of the schedule of milestone payments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-1-formation-and-business-of-the-company" ], "lang": { "en-us": { "role": { "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12", "r792" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-tables" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]", "documentation": "Tabular disclosure of asset acquired and liability assumed in business combination and recognized at acquisition date." } } }, "auth_ref": [ "r1266", "r1268" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r38", "r39", "r40" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r38", "r39", "r40" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r512", "r514", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r539", "r540", "r541", "r542", "r543", "r544", "r549" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r16", "r17", "r127" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r131" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-tables" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r47", "r48", "r49", "r50", "r51", "r52", "r123", "r124", "r125", "r200", "r201", "r202", "r321", "r480", "r481", "r483", "r484", "r485", "r486", "r487", "r707", "r877", "r878", "r879", "r880", "r1025", "r1131", "r1170", "r1172" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r1224" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r589", "r1036" ] }, "tivc_ScorpiusHoldingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ScorpiusHoldingsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details" ], "lang": { "en-us": { "role": { "label": "Scorpius Holdings [Member]", "documentation": "Scorpius Holdings" } } }, "auth_ref": [] }, "tivc_SecondTrancheClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SecondTrancheClosingMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Second Tranche Closing [Member]", "documentation": "The Second Tranche Closing." } } }, "auth_ref": [] }, "tivc_SecondTrancheClosingPlacementAgentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SecondTrancheClosingPlacementAgentServicesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Second Tranche Closing, Placement Agent Services [Member]", "documentation": "Stock sold during the second tranche closing, as payment for placement agent services." } } }, "auth_ref": [] }, "tivc_SecondTrancheInvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SecondTrancheInvestorWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Second Tranche Investor Warrants [Member]", "documentation": "Represents the second tranche investor warrants." } } }, "auth_ref": [] }, "tivc_SecondTrancheWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SecondTrancheWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Second Tranche Warrants [Member]", "documentation": "Second Tranche Warrants." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1092" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SecurityDeposit", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SecurityDeposit", "terseLabel": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r1145" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1094" ] }, "us-gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentContinuingOperationsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Continuing Operations [Member]", "documentation": "Component of an entity expected to operate in the foreseeable future." } } }, "auth_ref": [] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": [ "r5", "r59", "r60", "r61" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r319", "r328", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r367", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r400", "r415", "r416", "r683", "r686", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r1008", "r1011", "r1012", "r1018", "r1078", "r1315", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344" ] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentOperatingActivitiesDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r145", "r319", "r327", "r328", "r329", "r330", "r331", "r343", "r345", "r346", "r358", "r359", "r360", "r361", "r362", "r364", "r365", "r367", "r1006", "r1009", "r1010", "r1011", "r1013", "r1015", "r1016" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r363", "r366", "r1007", "r1008", "r1014" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r103", "r994", "r995", "r996", "r999", "r1165" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [ "r1038", "r1043" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r1146", "r1147", "r1219", "r1223" ] }, "tivc_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SeriesAWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]", "documentation": "Series A warrants." } } }, "auth_ref": [] }, "tivc_SeriesBDividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SeriesBDividendsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Series B Dividends [Member]", "documentation": "Relating to series B dividends." } } }, "auth_ref": [] }, "tivc_SeriesBPreferredStockAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SeriesBPreferredStockAndWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock and Warrants [Member]", "documentation": "Relating to Series B preferred stock and warrants." } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r1146", "r1147", "r1219", "r1223" ] }, "tivc_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SeriesBWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Series B Warrants [Member]", "documentation": "Series B warrants." } } }, "auth_ref": [] }, "tivc_SeriesCDividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SeriesCDividendsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Series C Dividends [Member]", "documentation": "Relating to series C dividends." } } }, "auth_ref": [] }, "tivc_SeriesCPreferredStockAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SeriesCPreferredStockAndWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock and Warrants [Member]", "documentation": "Relating to Series C preferred stock and warrants." } } }, "auth_ref": [] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r1146", "r1147", "r1219", "r1223" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock based compensation", "label": "us-gaap_ShareBasedCompensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1034" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "terseLabel": "Forfeited (in shares)", "negatedTerseLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r533" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "terseLabel": "Forfeited, weighted average grant date fair value (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r533" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Issuance of restricted common stock, shares (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r531" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Issuance of restricted common stock, weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r531" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodStartLabel": "Balance, shares (in shares)", "periodEndLabel": "Balance, shares (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r528", "r529" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Balance, weighted average grant date fair value (in dollars per share)", "periodEndLabel": "Balance, weighted average grant date fair value (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r528", "r529" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "terseLabel": "Vested (in shares)", "negatedTerseLabel": "Vested, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r532" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r535" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Vested, weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r532" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r542" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Expected volatility, maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r541" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Expected volatility, minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r541" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate, maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r543" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate, minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r543" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r128", "r129" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1254" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1035" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)", "periodStartLabel": "Balance, available for grant (in shares)", "periodEndLabel": "Balance, available for grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r53" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Options expired, number of options (in shares)", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r527" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Options forfeited / cancelled, number of options (in shares)", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r526" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Options granted, number of options (in shares)", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r524" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Options granted, weighted average grant date fair value (in dollars per share)", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r534" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodStartLabel": "Balances, aggregate intrinsic value", "periodEndLabel": "Balances, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r53" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Balances, number of options (in shares)", "periodEndLabel": "Balances, number of options (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r520", "r521" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Balances, weighted average exercise price (in dollars per share)", "periodEndLabel": "Balances, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r520", "r521" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested and exercisable, aggregate intrinsic value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r537" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested and exercisable, number of options (in shares)", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r537" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Vested and exercisable, weighted average exercise price (in dollars per share)", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r537" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r536" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r540", "r541", "r542", "r543", "r544" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "Options forfeited / cancelled, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r526" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "Options granted, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r524" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [ "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r511", "r519", "r538", "r539", "r540", "r541", "r544", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562" ] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Employee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r514", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r540", "r541", "r542", "r543", "r544" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1228" ] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "Canceled (in shares)", "negatedLabel": "Cancelled, shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details" ], "lang": { "en-us": { "role": { "label": "Cancelled, weighted average grant date fair value (in dollars per share)", "terseLabel": "Canceled (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardExercisePricePercentOfMarketValuePerShare": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExercisePricePercentOfMarketValuePerShare", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardExercisePricePercentOfMarketValuePerShare", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price, Percent of Market Value per Share", "documentation": "The exercise price of the stock options, as a percent of the fair market value of the company's stock on the date of the grant." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details" ], "lang": { "en-us": { "role": { "label": "Expected life (in years) (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r540" ] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantAddedPerAmendmentAnnualShMtg": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantAddedPerAmendmentAnnualShMtg", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "Added per amendment annual shareholder meeting, available for grant (in shares)", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Added Per Amendment Annual S/H Mtg." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Options exercised, available for grant (in shares)", "label": "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Options Exercised." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExpired", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Options expired, available for grant (in shares)", "label": "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExpired", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Options Expired." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsForfeited", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "Options forfeited / cancelled, available for grant (in shares)", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Options Forfeited." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "Options granted, available for grant (in shares)", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Options Granted." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsRoundedForReverseStockSplit": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsRoundedForReverseStockSplit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Options rounded for reverse stock split, available for grant (in shares)", "label": "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantOptionsRoundedForReverseStockSplit", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Options Rounded for Reverse Stock Split." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantReservedSharesCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantReservedSharesCancelled", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Reserved shares cancelled, available for grant (in shares)", "label": "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantReservedSharesCancelled", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Reserved Shares Cancelled." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantRsasGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantRsasGranted", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "RSAs granted, available for grant (in shares)", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Rsas Granted." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantRsusForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantRsusForfeited", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "RSUs forfeited, available for grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantRsusGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantRsusGranted", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "RSUs granted, available for grant (in shares)", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Rsus Granted." } } }, "auth_ref": [] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares reserved for issuance, available for grant (in shares)", "label": "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Shares Reserved for Issuance." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r53" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested and exercisable, weighted average remaining contractual life (Year)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r53" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Options forfeited / cancelled, weighted average grant date fair value (in dollars per share)", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "documentation": "Weighted average grant-date fair value of non-vested options forfeited." } } }, "auth_ref": [ "r1254" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Balances, weighted average grant date fair value (in dollars per share)", "periodEndLabel": "Balances, weighted average grant date fair value (in dollars per share)", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [ "r1254" ] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOptionsRoundedForReverseStockSplit": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOptionsRoundedForReverseStockSplit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "Options rounded for reverse stock split, number of options (in shares)", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Options Rounded for Reverse Stock Split." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r130" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "Vested and exercisable, weighted average grant date fair value (in dollars per share)", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [ "r1254" ] }, "tivc_SharebasedCompensationArrangementBySharebasedPaymentAwardRsusGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardRsusGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "label": "RSUs granted inside pool, weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average grant-date fair value of RSUs granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [] }, "tivc_SharebasedPaymentArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedPaymentArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_SharebasedPaymentArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue", "terseLabel": "Share-based Payment Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Total Fair Value", "documentation": "Share-based Payment Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Total Fair Value" } } }, "auth_ref": [] }, "tivc_SharebasedPaymentArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfSharesOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SharebasedPaymentArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfSharesOutstanding", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_SharebasedPaymentArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAuthorizedPercentageOfSharesOutstanding", "terseLabel": "Share-based Payment Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Shares Outstanding", "documentation": "Share-based Payment Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Shares Outstanding" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesOutstanding", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details" ], "lang": { "en-us": { "role": { "label": "Short term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r789", "r1067" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r269", "r270" ] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r1213" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r576" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r188", "r319", "r328", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r367", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r400", "r404", "r415", "r416", "r683", "r686", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r1008", "r1011", "r1012", "r1018", "r1078", "r1315", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r157", "r200", "r201", "r202", "r271", "r275", "r306", "r307", "r310", "r313", "r321", "r322", "r371", "r426", "r428", "r429", "r430", "r433", "r434", "r468", "r469", "r471", "r472", "r474", "r478", "r480", "r481", "r484", "r485", "r487", "r767", "r877", "r878", "r879", "r880", "r883", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r913", "r933", "r951", "r970", "r971", "r972", "r973", "r974", "r1131", "r1172", "r1174", "r1184" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r93", "r96", "r97", "r173", "r180", "r181", "r211", "r212", "r213", "r283", "r284", "r285", "r288", "r297", "r300", "r302", "r320", "r372", "r375", "r402", "r466", "r490", "r552", "r603", "r604", "r618", "r619", "r620", "r623", "r695", "r696", "r710", "r712", "r713", "r714", "r715", "r717", "r718", "r719", "r720", "r721", "r730", "r771", "r772", "r773", "r774", "r775", "r776", "r780", "r782", "r802", "r839", "r859", "r860", "r861", "r883", "r951" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-1-formation-and-business-of-the-company", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details", "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-tables", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-schedule-of-note-payable-details", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-tables", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-tables", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-tables", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-tables", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-unrecognized-tax-benefits-details", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-tables", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-tables", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-tables", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-tables", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-tables", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-schedule-of-pro-forma-information-details", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-tables", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-tables", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-summary-of-inventory-details", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-tables", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-tables", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-tables", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-lease-costs-details", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-tables", "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r283", "r284", "r285", "r320", "r468", "r469", "r471", "r474", "r782", "r815", "r875", "r884", "r895", "r905", "r906", "r907", "r908", "r909", "r910", "r913", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r926", "r927", "r928", "r929", "r930", "r934", "r935", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r951", "r997", "r999", "r1084", "r1348" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-schedule-of-segment-information-details" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementScenarioAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-details-textual" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r168", "r185", "r187", "r303", "r510", "r1132", "r1133" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r283", "r284", "r285", "r320", "r370", "r468", "r469", "r471", "r474", "r782", "r815", "r875", "r884", "r895", "r905", "r906", "r907", "r908", "r909", "r910", "r913", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r926", "r927", "r928", "r929", "r930", "r934", "r935", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r951", "r997", "r999", "r1084", "r1348" ] }, "tivc_StateraAndAvenueSecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StateraAndAvenueSecuritiesPurchaseAgreementMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Statera and Avenue Securities Purchase Agreement [Member]", "documentation": "The SPA with Statera and Avenue." } } }, "auth_ref": [] }, "tivc_StateraLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StateraLicenseAgreementMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Statera License Agreement [Member]", "documentation": "The Statera License." } } }, "auth_ref": [] }, "tivc_StateraLicenseAgreementNeutropeniaOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StateraLicenseAgreementNeutropeniaOptionMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Statera License Agreement, Neutropenia Option [Member]", "documentation": "The Neutropenia Option under the Statera License Agreement." } } }, "auth_ref": [] }, "tivc_StateraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StateraMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual" ], "lang": { "en-us": { "role": { "label": "Statera [Member]", "documentation": "Statera." } } }, "auth_ref": [] }, "tivc_StateraSecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StateraSecuritiesPurchaseAgreementMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Statera Securities Purchase Agreement [Member]", "documentation": "The Statera SPA." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of equity", "label": "us-gaap_StockIssued1", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "tivc_StockIssuedDuringPeriodSharesCommonStockAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodSharesCommonStockAndWarrants", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants, net of issuance costs and warrants issued to placement agents (in shares)", "documentation": "Number of shares issuance of common stock and warrants, net of issuance costs and warrants issued to placement agents." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Conversion of preferred stock into common stock (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r15", "r49", "r93", "r96", "r125", "r452" ] }, "tivc_StockIssuedDuringPeriodSharesEquityLineOfCredit": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodSharesEquityLineOfCredit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for equity line of credit (in shares)", "documentation": "The number of shares issued during the period for an equity line of credit." } } }, "auth_ref": [] }, "tivc_StockIssuedDuringPeriodSharesExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants (in shares)", "documentation": "The number of shares issued in the period as a result of the exercise of warrants." } } }, "auth_ref": [] }, "tivc_StockIssuedDuringPeriodSharesFractionalShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodSharesFractionalShares", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_StockIssuedDuringPeriodSharesFractionalShares", "terseLabel": "Stock Issued During Period, Shares, Fractional Shares (in shares)", "documentation": "The number of fractional shares issued during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock and preferred stock, net of issuance costs (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r15", "r92", "r93", "r125", "r877", "r951", "r971" ] }, "tivc_StockIssuedDuringPeriodSharesPreferredStockAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodSharesPreferredStockAndWarrants", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of preferred stock and warrants, net of issuance costs and warrants to placement agents (in shares)", "documentation": "Number of shares issued of preferred stock and warrants, net of issuance costs and warrants to placement agents" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for restricted stock award (in shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r15", "r125" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Settlement of restricted stock units (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r15", "r92", "r93", "r125" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-options-activity-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Options exercised, number of options (in shares)", "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r15", "r92", "r93", "r125", "r525" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesStockSplits", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock in lieu of fractional shares for stock split (in shares)", "documentation": "Number of shares issued during the period as a result of a stock split." } } }, "auth_ref": [ "r15", "r92", "r93", "r125" ] }, "tivc_StockIssuedDuringPeriodSharesTotalWholeSharesIssuedInsteadOfFractionalShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodSharesTotalWholeSharesIssuedInsteadOfFractionalShares", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_StockIssuedDuringPeriodSharesTotalWholeSharesIssuedInsteadOfFractionalShares", "terseLabel": "Stock Issued During Period, Shares, Total Whole Shares Issued Instead of Fractional Shares (in shares)", "documentation": "The total number of whole shares issued instead of fractional shares." } } }, "auth_ref": [] }, "tivc_StockIssuedDuringPeriodSharesWholeSharesIssuedInsteadOfFractionalShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodSharesWholeSharesIssuedInsteadOfFractionalShares", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "tivc_StockIssuedDuringPeriodSharesWholeSharesIssuedInsteadOfFractionalShares", "terseLabel": "Stock Issued During Period, Shares, Whole Shares Issued Instead of Fractional Shares (in shares)", "documentation": "The number of whole shares issued to stockholders that would otherwise have received fractional shares." } } }, "auth_ref": [] }, "tivc_StockIssuedDuringPeriodValueCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodValueCommonStockAndWarrants", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants, net of issuance costs and warrants issued to placement agents", "documentation": "Amount of issuance of common stock and warrants, net of issuance costs and warrants issued to placement agents." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Conversion of preferred stock into common stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r15", "r93", "r96", "r97", "r125" ] }, "tivc_StockIssuedDuringPeriodValueEquityLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodValueEquityLineOfCredit", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for equity line of credit", "documentation": "Stock Issued During Period, Value, Equity Line of Credit" } } }, "auth_ref": [] }, "tivc_StockIssuedDuringPeriodValueExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants", "documentation": "The value of the shares issued during the period as a result of the exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock and preferred stock, net of issuance costs", "terseLabel": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r15", "r92", "r93", "r125", "r883", "r951", "r971", "r1090" ] }, "tivc_StockIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "StockIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of preferred stock and warrants, net of issuance costs and warrants to placement agents", "documentation": "Number of shares issuance of preferred stock and warrants, net of issuance costs and warrants issued to placement agents." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for restricted stock award", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r15", "r92", "r93", "r125" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Settlement of restricted stock units", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r15", "r125" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details" ], "lang": { "en-us": { "role": { "label": "Total equity", "totalLabel": "Total Stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r93", "r96", "r97", "r109", "r915", "r931", "r952", "r953", "r1076", "r1091", "r1170", "r1174", "r1175", "r1198", "r1293", "r1351" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r126" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r777", "r805" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTable", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r777", "r805" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r777", "r805" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r777", "r805" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r804", "r806" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "tivc_SummaryOfReservedSharesOfStockTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "SummaryOfReservedSharesOfStockTableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-tables" ], "lang": { "en-us": { "role": { "label": "Summary of Reserved Shares of Stock [Table Text Block]", "documentation": "Tabular disclosure of reserved shares of stock." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TableTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-tables", "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-tables", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-tables", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-tables", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-tables", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-tables", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-tables", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-tables", "http://www.tivichealth.com/20251231/role/statement-note-19-segment-information-tables", "http://www.tivichealth.com/20251231/role/statement-note-3-discontinued-operations-tables", "http://www.tivichealth.com/20251231/role/statement-note-4-business-combination-tables", "http://www.tivichealth.com/20251231/role/statement-note-5-financial-instruments-and-fair-value-measurements-tables", "http://www.tivichealth.com/20251231/role/statement-note-6-inventory-net-tables", "http://www.tivichealth.com/20251231/role/statement-note-7-property-and-equipment-net-tables", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-tables", "http://www.tivichealth.com/20251231/role/statement-note-9-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r601" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r601" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r601" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_TaxesPayableCurrent", "terseLabel": "Delaware franchise tax", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r80", "r81" ] }, "us-gaap_TemporaryEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquityAbstract", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Temporary equity" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityAccretionOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquityAccretionOfDividends", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "verboseLabel": "Dividends declared on preferred stock", "label": "us-gaap_TemporaryEquityAccretionOfDividends", "documentation": "Value of accretion of temporary equity during the period due to unpaid dividends." } } }, "auth_ref": [ "r1218", "r1220", "r1221", "r1222" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets", "http://www.tivichealth.com/20251231/role/statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Temporary equity", "label": "us-gaap_TemporaryEquityCarryingAmountAttributableToParent", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r426", "r428", "r429", "r430", "r433", "r434", "r468", "r469", "r471", "r475", "r563", "r565", "r830" ] }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r91", "r271", "r275", "r371", "r468", "r469", "r471", "r472", "r474", "r475", "r1174", "r1222", "r1293" ] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Temporary equity, par value (in dollars per share)", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r21" ] }, "tivc_TemporaryEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "TemporaryEquityPolicyTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Temporary Equity [Policy Text Block]", "documentation": "The company's policy regarding temporary equity." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquitySharesAuthorized", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Temporary equity, authorized (in shares)", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r91", "r471" ] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Temporary equity, issued (in shares)", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r91", "r471" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Temporary equity, outstanding (in shares)", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r91", "r471" ] }, "tivc_The2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "The2021PlanMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2021 Plan [Member]", "documentation": "The 2021 Plan." } } }, "auth_ref": [] }, "tivc_ThinkequityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ThinkequityMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "ThinkEquity [Member]", "documentation": "ThinkEquity." } } }, "auth_ref": [] }, "tivc_ThirdTrancheClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ThirdTrancheClosingMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Third Tranche Closing [Member]", "documentation": "Represents the third tranche closing." } } }, "auth_ref": [] }, "tivc_ThirdTrancheClosingPlacementAgentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ThirdTrancheClosingPlacementAgentServicesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Third Tranche Closing, Placement Agent Services [Member]", "documentation": "Stock sold during the third tranche closing, as payment for placement agent services." } } }, "auth_ref": [] }, "tivc_ThirdTrancheInvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ThirdTrancheInvestorWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Third Tranche Investor Warrants [Member]", "documentation": "Relating to third tranche investor warrants." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r1194", "r1302" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r1195", "r1196", "r1197" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1115" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "tivc_TrancheClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "TrancheClosingMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Tranche Closing [Member]", "documentation": "The tranche closing." } } }, "auth_ref": [] }, "tivc_TrancheClosingPlacementAgentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "TrancheClosingPlacementAgentServicesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Tranche Closing, Placement Agent Services [Member]", "documentation": "Placement agent services in the tranche closing." } } }, "auth_ref": [] }, "tivc_TrancheClosingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "TrancheClosingWarrantsMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Tranche Closing Warrants [Member]", "documentation": "Tranche Closing warrants." } } }, "auth_ref": [] }, "tivc_TumimPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "TumimPurchaseAgreementMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events", "http://www.tivichealth.com/20251231/role/statement-note-20-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Tumim Purchase Agreement [Member]", "documentation": "Tumim Purchase Agreement" } } }, "auth_ref": [] }, "tivc_TwoWarrantsIssuedInAugust2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "TwoWarrantsIssuedInAugust2025Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "Two Warrants Issued in August 2025 [Member]", "documentation": "Represents the two warrants issued in August 2025." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r697" ] }, "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UndistributedEarningsLossAvailableToCommonShareholdersBasic", "crdr": "credit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic", "totalLabel": "Net loss attributed to Tivic Health Systems, Inc.", "documentation": "Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings." } } }, "auth_ref": [ "r309", "r311" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-unrecognized-tax-benefits-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefits", "terseLabel": "Unrecognized Tax Benefits", "periodStartLabel": "Unrecognized tax benefits, beginning of year", "periodEndLabel": "Unrecognized tax benefits, end of year", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r571", "r589", "r1036" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r587", "r1036" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r587", "r1036" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-schedule-of-unrecognized-tax-benefits-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r590", "r1036" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UseOfEstimates", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r149", "r150", "r323", "r324", "r325", "r326", "r819", "r821", "r1003" ] }, "tivc_ValidationOfCurrentInventoryOfMaterialsForDistributionAndSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "ValidationOfCurrentInventoryOfMaterialsForDistributionAndSalesMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details" ], "lang": { "en-us": { "role": { "label": "Validation of Current Inventory of Materials for Distribution and Sales [Member]", "documentation": "The validation of current inventory of materials for distribution and sale." } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-16-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r593" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "VestingAxis", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "VestingDomain", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans", "http://www.tivichealth.com/20251231/role/statement-note-15-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253" ] }, "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Deemed dividends on purchase warrants for common shares", "terseLabel": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount", "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity." } } }, "auth_ref": [ "r487", "r489" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantMember", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r1081", "r1082", "r1085", "r1086", "r1087", "r1088" ] }, "tivc_WarrantsAndRightsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsAndRightsDisclosureTextBlock", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Disclosure [Text Block]", "documentation": "Disclosure of warrants and rights." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r1285", "r1286", "r1287" ] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Expiration date of warrants", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r1285", "r1286", "r1287" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrant measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r1285", "r1286", "r1287" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-11-convertible-note-payable-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-12-preferred-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-13-common-stock-details-textual", "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1285", "r1286", "r1287" ] }, "tivc_WarrantsExpiringAugust112029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringAugust112029Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring August 11, 2029 [Member]", "documentation": "Warrants Expiring August 11, 2029." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringAugust212029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringAugust212029Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring August 21, 2029 [Member]", "documentation": "Warrants Expiring August 21, 2029." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringAugust212030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringAugust212030Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring August 21, 2030 [Member]", "documentation": "Warrants Expiring August 21, 2030." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringAugust42028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringAugust42028Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring August 4, 2028 [Member]", "documentation": "Warrants Expiring August 4, 2028." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringAugust92027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringAugust92027Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring August 9, 2027 [Member]", "documentation": "Warrants Expiring August 9, 2027." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringDecember1020301Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringDecember1020301Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring December 10, 2030 1 [Member]", "documentation": "Relating to warrants expiring December 10, 2030." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringDecember1020302Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringDecember1020302Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring December 10, 2030 2 [Member]", "documentation": "Relating to warrants expiring December 10, 2030 2." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringJuly102028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringJuly102028Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring July 10, 2028 [Member]", "documentation": "Warrants Expiring July 10, 2028." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringJuly12026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringJuly12026Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring July 1, 2026 [Member]", "documentation": "Warrants Expiring July 1, 2026." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringJuly142028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringJuly142028Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring July 14, 2028 [Member]", "documentation": "Warrants Expiring July 14, 2028." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringJuly312029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringJuly312029Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring July 31, 2029 [Member]", "documentation": "Warrants Expiring June 31, 2029." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringJuly312030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringJuly312030Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring July 31, 2030 [Member]", "documentation": "Warrants Expiring July 31, 2030." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringJune252029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringJune252029Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring June 25, 2029 [Member]", "documentation": "Warrants Expiring June 25, 2029." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringJune252030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringJune252030Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring June 25, 2030 [Member]", "documentation": "Warrants Expiring June 25, 2030." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringMay142029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringMay142029Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring May 14, 2029 [Member]", "documentation": "Warrants Expiring May 14, 2029." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringMay92029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringMay92029Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring May 9, 2029 [Member]", "documentation": "Warrants Expiring May 9, 2029." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringNovember102026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringNovember102026Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring November 10, 2026 [Member]", "documentation": "Warrants Expiring November 10, 2026." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringNovember152026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringNovember152026Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring November 15, 2026 [Member]", "documentation": "Warrants Expiring November 15, 2026." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringSeptember262029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringSeptember262029Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring September 26, 2029 [Member]", "documentation": "Warrants Expiring September 26, 2029." } } }, "auth_ref": [] }, "tivc_WarrantsExpiringSeptember262030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsExpiringSeptember262030Member", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring September 26, 2030 [Member]", "documentation": "Warrants Expiring September 26, 2030." } } }, "auth_ref": [] }, "tivc_WarrantsIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsIssued1", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Warrants issued to placement agents as non-cash offering fees", "documentation": "Represents the noncash effect of warrants issued." } } }, "auth_ref": [] }, "tivc_WarrantsIssuedInExchangeForDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WarrantsIssuedInExchangeForDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Non-cash recognition of embedded derivative liability on issuance of convertible notes", "documentation": "Represents the noncash effect of warrants issued in exchange for derivative liability." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-operations", "http://www.tivichealth.com/20251231/role/statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average number of shares - basic and diluted (in shares)", "terseLabel": "Basic and diluted weighted average number of shares outstanding (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r305", "r313" ] }, "tivc_WriteOffOfOfferingCostsFromUnclosedArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "WriteOffOfOfferingCostsFromUnclosedArrangement", "crdr": "debit", "calculation": { "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.tivichealth.com/20251231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Write-off offering costs related to unclosed financing arrangements", "label": "tivc_WriteOffOfOfferingCostsFromUnclosedArrangement", "documentation": "Represents the amount written off of offering costs from an unclosed arrangement." } } }, "auth_ref": [] }, "tivc_statement-statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-10-other-accrued-expenses-summary-of-other-accrued-expenses-details", "lang": { "en-us": { "role": { "label": "Note 10 - Other Accrued Expenses - Summary of Other Accrued Expenses (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-10-other-accrued-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-10-other-accrued-expenses-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Other Accrued Expenses" } } }, "auth_ref": [] }, "tivc_statement-statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-11-convertible-note-payable-future-payments-of-the-note-payable-details", "lang": { "en-us": { "role": { "label": "Note 11 - Convertible Note Payable - Future Payments of the Note Payable (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-11-convertible-note-payable-schedule-of-note-payable-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-11-convertible-note-payable-schedule-of-note-payable-details", "lang": { "en-us": { "role": { "label": "Note 11 - Convertible Note Payable - Schedule of Note Payable (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-11-convertible-note-payable-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-11-convertible-note-payable-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Convertible Note Payable" } } }, "auth_ref": [] }, "tivc_statement-statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-13-common-stock-summary-of-reserved-shares-of-common-stock-details", "lang": { "en-us": { "role": { "label": "Note 13 - Common Stock - Summary of Reserved Shares of Common Stock (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-13-common-stock-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-13-common-stock-tables", "lang": { "en-us": { "role": { "label": "Note 13 - Common Stock" } } }, "auth_ref": [] }, "tivc_statement-statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-14-common-stock-warrants-fair-value-measurements-of-warrants-details", "lang": { "en-us": { "role": { "label": "Note 14 - Common Stock Warrants - Fair Value Measurements of Warrants (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-14-common-stock-warrants-summary-of-outstanding-warrants-details", "lang": { "en-us": { "role": { "label": "Note 14 - Common Stock Warrants - Summary of Outstanding Warrants (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-14-common-stock-warrants-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-14-common-stock-warrants-tables", "lang": { "en-us": { "role": { "label": "Note 14 - Common Stock Warrants" } } }, "auth_ref": [] }, "tivc_statement-statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-15-equity-incentive-plans-fair-value-of-sharedbased-payment-awards-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Fair Value of Shared-based Payment Awards (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-15-equity-incentive-plans-options-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-15-equity-incentive-plans-options-activity-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Options Activity (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-15-equity-incentive-plans-summary-of-restricted-stock-awards-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Summary of Restricted Stock Awards (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-15-equity-incentive-plans-summary-of-stockbased-compensation-details", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans - Summary of Stock-based Compensation (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-15-equity-incentive-plans-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-15-equity-incentive-plans-tables", "lang": { "en-us": { "role": { "label": "Note 15 - Equity Incentive Plans" } } }, "auth_ref": [] }, "tivc_statement-statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-16-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 16 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details", "lang": { "en-us": { "role": { "label": "Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-16-income-taxes-schedule-of-unrecognized-tax-benefits-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-16-income-taxes-schedule-of-unrecognized-tax-benefits-details", "lang": { "en-us": { "role": { "label": "Note 16 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-16-income-taxes-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-16-income-taxes-tables", "lang": { "en-us": { "role": { "label": "Note 16 - Income Taxes" } } }, "auth_ref": [] }, "tivc_statement-statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-17-net-loss-per-share-calculation-of-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note 17 - Net Loss per Share - Calculation of Earnings per Share (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-17-net-loss-per-share-summary-of-antidilutive-securities-details", "lang": { "en-us": { "role": { "label": "Note 17 - Net Loss per Share - Summary of Antidilutive Securities (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-17-net-loss-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-17-net-loss-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 17 - Net Loss per Share" } } }, "auth_ref": [] }, "tivc_statement-statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-18-revision-of-previously-issued-financial-statements-schedule-of-revised-financial-statements-details", "lang": { "en-us": { "role": { "label": "Note 18 - Revision of Previously Issued Financial Statements - Schedule of Revised Financial Statements (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-18-revision-of-previously-issued-financial-statements-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-18-revision-of-previously-issued-financial-statements-tables", "lang": { "en-us": { "role": { "label": "Note 18 - Revision of Previously Issued Financial Statements" } } }, "auth_ref": [] }, "tivc_statement-statement-note-19-segment-information-schedule-of-segment-information-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-19-segment-information-schedule-of-segment-information-details", "lang": { "en-us": { "role": { "label": "Note 19 - Segment Information - Schedule of Segment Information (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-19-segment-information-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-19-segment-information-tables", "lang": { "en-us": { "role": { "label": "Note 19 - Segment Information" } } }, "auth_ref": [] }, "tivc_statement-statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-3-discontinued-operations-significant-items-from-discontinued-operations-details", "lang": { "en-us": { "role": { "label": "Note 3 - Discontinued Operations - Significant Items from Discontinued Operations (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-3-discontinued-operations-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-3-discontinued-operations-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Discontinued Operations" } } }, "auth_ref": [] }, "tivc_statement-statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-4-business-combination-assets-acquired-and-liabilities-assumed-details", "lang": { "en-us": { "role": { "label": "Note 4 - Business Combination - Assets Acquired and Liabilities Assumed (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-4-business-combination-schedule-of-pro-forma-information-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-4-business-combination-schedule-of-pro-forma-information-details", "lang": { "en-us": { "role": { "label": "Note 4 - Business Combination - Schedule of Pro Forma Information (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-4-business-combination-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-4-business-combination-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Business Combination" } } }, "auth_ref": [] }, "tivc_statement-statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-5-financial-instruments-and-fair-value-measurements-schedule-of-recurring-fair-value-measurements-details", "lang": { "en-us": { "role": { "label": "Note 5 - Financial Instruments and Fair Value Measurements - Schedule of Recurring Fair Value Measurements (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-5-financial-instruments-and-fair-value-measurements-summary-of-cash-equivalents-fair-value-details", "lang": { "en-us": { "role": { "label": "Note 5 - Financial Instruments and Fair Value Measurements - Summary of Cash Equivalents' Fair Value (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-5-financial-instruments-and-fair-value-measurements-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-5-financial-instruments-and-fair-value-measurements-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Financial Instruments and Fair Value Measurements" } } }, "auth_ref": [] }, "tivc_statement-statement-note-6-inventory-net-summary-of-inventory-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-6-inventory-net-summary-of-inventory-details", "lang": { "en-us": { "role": { "label": "Note 6 - Inventory, Net - Summary of Inventory (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-6-inventory-net-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-6-inventory-net-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Inventory, Net" } } }, "auth_ref": [] }, "tivc_statement-statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-7-property-and-equipment-net-summary-of-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 7 - Property and Equipment, Net - Summary of Property and Equipment (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-7-property-and-equipment-net-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-7-property-and-equipment-net-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Property and Equipment, Net" } } }, "auth_ref": [] }, "tivc_statement-statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-8-statera-license-agreement-schedule-of-milestone-payments-details", "lang": { "en-us": { "role": { "label": "Note 8 - Statera License Agreement - Schedule of Milestone Payments (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-8-statera-license-agreement-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-8-statera-license-agreement-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Statera License Agreement" } } }, "auth_ref": [] }, "tivc_statement-statement-note-9-commitments-and-contingencies-lease-costs-details": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-9-commitments-and-contingencies-lease-costs-details", "lang": { "en-us": { "role": { "label": "Note 9 - Commitments and Contingencies - Lease Costs (Details)" } } }, "auth_ref": [] }, "tivc_statement-statement-note-9-commitments-and-contingencies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-note-9-commitments-and-contingencies-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Commitments and Contingencies" } } }, "auth_ref": [] }, "tivc_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.tivichealth.com/20251231", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "3", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column B", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column C", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 1.B.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-26" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-28" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-8" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "66", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3A" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805-10/tableOfContent" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-4" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-5" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805-20/tableOfContent" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805-30/tableOfContent" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479326/805-40-45-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2G", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-12" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "805", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r984": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r985": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r986": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r987": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r988": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15" }, "r989": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r990": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20" }, "r991": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r992": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r993": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r994": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r995": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r996": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r997": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r998": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24" }, "r999": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r1000": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1001": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1002": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1003": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r1004": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1005": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1008": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1011": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1012": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1013": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1014": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1017": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1018": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1021": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1024": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r1025": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1027": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1030": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1031": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1032": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1034": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1035": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39" }, "r1043": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r1044": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42" }, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r1046": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "45", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-45" }, "r1047": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "46", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-46" }, "r1048": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r1049": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-49" }, "r1050": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-50" }, "r1051": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r1052": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r1053": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r1054": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13" }, "r1055": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r1056": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "184", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184" }, "r1057": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1058": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1059": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1060": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1061": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1062": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1063": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1065": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1067": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1068": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r1070": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r1071": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r1072": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5" }, "r1073": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r1075": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r1076": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1077": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1078": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1079": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r1080": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r1081": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1082": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1084": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1085": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1087": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1088": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1089": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1090": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1092": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1093": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1094": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1095": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1096": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1097": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1098": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1099": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1100": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1101": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1102": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1103": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1104": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1105": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1106": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1107": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1108": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1109": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1110": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1111": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1112": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1113": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1114": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1115": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1116": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1117": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1118": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1119": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1120": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1121": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1122": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1123": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1124": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1125": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1126": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1127": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1128": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1129": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1130": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r1131": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1132": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1133": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Subparagraph": "(a)", "Publisher": "SEC" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-27" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481116/815-15-25-1" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } }